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Abstract  
Tumor hypoxia is a major indicator of treatment resistance to chemotherapeutic drugs and 
fluorescence optical tomography has tremendous potential to provide clinically useful 
functional information by targeting tumor hypoxia. The current techniques to detect hypoxia 
involve invasive and non-invasive probes, for example MRI, PET (non-invasive) and 
polarographic needle electrodes (invasive). The polarographic needle electrode technique is 
limited to superficial tumors, such as cervix, neck, and head. Non-invasive techniques such 
as Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) are 
expensive for routine clinical use and these techniques suffers from low spatial resolution, 
high back ground counts, needs an injection of radioactive tracer. Therefore there is a need 
for a cheap and non-invasive and safe technique for imaging hypoxia in tumors which would 
improve the cancer therapy outcomes. The aim of this dissertation is to design a cheap and 
non-invasive method to image hypoxia in tumor cells. In this dissertation, synthesis, 
photophysical characterization and hypoxia evaluation of a series of 2-nitroimidazole 
coupled indocyanine green dyes (first, second and third generation) is presented. In the first 
generation, 2-nitroimidazoles were coupled to indocyanine gree (ICG) via ethanolamine
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linker and in the third generation ethanolamine was replaced with a piperazine unit. The third 
generation has the same piperazine linker but linked to a rigid dye (pentamethine dye). 
Among the three generations, the third generation dyes are effective in providing a strong 
fluorescence signal and stayed much longer (up to 24h) in the hypoxic regions of tumor cells. 
 
We have observed that incorporation of a methyl group distal to a terminal long-chain alkyne 
leads to an increased rate of isomerization to the corresponding internal alkyne upon 
treatment with a strong base, in DMSO. When compared to a long-straight chain terminal 
alkyne, the isobranch analog isomerizes about three times faster under identical conditions. 
In both cases, equilibration to a 95-97:5-3 mixture of internal:terminal  alkyne follows 
isomerization. The difference in rate may be due to conformational effects that involve 
folding of the alkyne, bringing the distal substituent close to the alkyne moiety. The 
isobranch may provide steric hindrance that disrupts such folding, making the propargylic 
proton or the terminal alkyne proton more available for reaction with base.
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Chapter 1.  
INTRODUCTION 
1.1 Cancer 
The human body is made up of trillions of living cells. Every day, these cells grow, 
divide or die in an orderly fashion. Cells divide at a much higher rate in children, allowing 
for growth in human body. After a certain age, cells divide to replace the dying cells or, to 
repair the injuries. On average, an adult human body creates 60 billion new cells each day; an 
equal number must die to maintain the cell count. When cells divide/grow, errors can happen 
in the DNA (deoxyribonucleic acid) sequence, which results the damaged DNA. The causes 
for DNA damage are diverse and complex; some of them are UV radiation, nuclear radiation, 
smoking, and carcinogenic chemicals. When DNA gets damaged, the cell can either repairs 
the DNA or it will die by apoptosis, which is a programmed cell death process. If apoptosis 
fails, the cell with defective DNA starts making new cells, all these new cells contains the 
DNA defect. These cells multiply abnormally, which results the accumulation of mass called 
a tumor (Figure 1.1). All tumors are not cancerous; tumors that cannot invade other tissues 
are called benign tumors. Benign tumors are not life threatening, except for the fact that they 
grow very large and stress healthy tissues and organs.1  
 
Figure 1.1. Loss of normal growth control in the cell2 
  Cancer cells can migrate to other part
lymph vessels, which is called metastasis
steps, for invasion of cancer cells into normal tissues, 
involves movement of cancer cells through the walls of lymph vessels or blood vessels,
circulation step in which cancer cells move t
to other parts of the body. Cancer cells stop migrating in small blood capillaries and then 
invade the walls of the capillaries to migrate into the surrounding 
extravasation. Proliferation is the step where cancer
known as micrometastases. 
cancer differ in terms of their growth rate and 
Figure 1.2. Migration of cancer cells to different part
1.2 Hypoxia  
  Blood supply is vital for tumor growth and
blood vessels form through the process called angiogenesis (
genesis means generation). 
irregular and leaky vascular network
supply to its vascular network
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s of the body through the 
 (Figure 1.2). Metastasis usually involves 
including an intravasation
hrough the lymphatic system a
tissue, which
 cells multiply to form small tumors 
All cancers are not same. For example, lung cancer and skin 
the way they respond to treatment
 
s of the body
 its sustenance. As a tumor grows
angio means blood vessel
The quick and uncontrolled growth of tumor cells results in 
s. As a result, when tumor grows bigger
 will be reduced, which impedes biological functions
 
bloodstream and 
several 
 step that 
 and a 
nd blood stream 
 is called as 
 techniques.3  
3
 
, new 
, and 
, the oxygen 
 of cancer 
 cells and leads to a tumor specific hypoxic region
low pH and low glucose concentration 
1.3).4-8  
Figure 
 Cells in the hypoxic regions are relatively inactive compared to highly proliferative 
cells. The slow growth rate in hypoxic regions and decreasing perfusion inhibits the 
effectiveness of the chemotherapy drugs
radicals from oxygen (O2) and 
which eventually leads to cell
reasons for the ineffectiveness of chemotherapy and radiotherapy. 
prolonged hypoxia eventually leads to drug resistance, enhanced metastatic abil
treatment failure.9 Given its significant role in tumor progression and 
traditional anti-cancer agents
for cancer therapy.  
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. This microenvironment of low oxygen,
in the tumor cell is characterized as 
1.3. Angiogenesis and hypoxia 
. In radiation therapy, radiation produces hydroxyl 
these radicals cause damage to the DNA 
 death. The slow growth rate and low levels of oxygen are the 
Studies have shown that 
resistance to the 
, hypoxia is emerging as an important and high
 
 
hypoxia (Figure 
 
of cancer cells, 
ity and 
 priority target 
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1.3 Hypoxia detection and Imaging techniques  
Radiation therapy is one of the current treatments available for cancer; this treatment 
uses photons to ionize atoms in the DNA molecule. Upon irradiation an oxygen molecule 
forms an excited state singlet oxygen, which generates hydroxyl radicals; these hydroxyl 
radicals are effective in killing the cells in their immediate area by damaging the DNA. The 
lifetime of singlet oxygen in aqueous media is short, so it cannot diffuse very far, which 
enables targeting of specific areas in the body. Radiation therapy has little effect on treating 
hypoxic cells because of low levels of oxygen, and the free radicals formed recombine 
without causing damage to the DNA. Hypoxic cells are less than three times more resistant to 
radiation therapy than well oxygenated cancer cells. Therefore, it is important to have an 
understanding of tumor hypoxia to treat cancer effectively. 
Current techniques to detect hypoxia involve invasive and non-invasive probes. 
Invasive techniques employ polarographic needle electrodes to measure partial pressure of 
oxygen in human tissue hypoxia. This technique is limited to superficial tumors, such as 
cervix,10 head and neck.11 Non-invasive techniques, Magnetic Resonance Imaging (MRI) and 
Positron Emission Tomography (PET) have been used to image hypoxia.  
In PET technique, a positron-emitting radioactive tracer is injected into the patient’s 
body, and radiation released by the tracer results in a three dimensional image of the body. 
The most commonly used PET scan imaging agent is 18F-labeled fluoromisonidazole 1 
(Figure 1.4). Nitroreductase activity (NO2 group reduction on imidazole ring) influences the 
retention time of fluoromisonidazole within the tissues and it’s delivery is not limited by 
perfusion.12 There are several limitations, which include low spatial resolution, a high 
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retention in the liver, high background counts, and a day long resting period between 
repeated doses.13 
 
N N
OH
18F
O2N
1
 
Figure 1.4. Fluoromisonidazole 
In an MRI technique, a magnetic field lines up the electrically charged particles 
(protons) of hydrogen nucleus and a radio frequency field is used to alter their alignment 
systematically. When protons relax back in to their ground state, energy is given out that will 
be used in constructing the three dimensional image of the body. With the help of contrasting 
agents and tracers, an estimation of tumor permeability can be determined. There are several 
types of MRIs and each type provides different characteristics of a tumor. For example, 
fluorine-containing contrast agents are sensitive to oxygen concentration; so the 19F-MRI can 
show the differences in oxygen concentration. Dynamic contrast-enhanced MRI (DCE-MRI) 
is a technique which provides the information about the properties of tumors such as 
distribution volume, permeability, and perfusion. Oxygen rich blood and oxygen poor blood 
behave differently in a magnetic field. BOLD-MRI (Blood oxygen level dependent MRI) 
works based on the difference between paramagnetic deoxyhemoglobin and diamagnetic 
oxyhemoglobin to image tumors, however this technique is not quantitative.12 
Both PET and MRI techniques have their own limitations. They are expensive for the 
routine clinical use, and PET system suffers from low spatial resolution, high background 
counts and needs an injection of radioactive tracer. Therefore, there is a great need for a 
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cheap, non-invasive and safe technique for imaging hypoxia in tumors which would improve 
the cancer therapy outcomes. 
Optical imaging is a non-invasive biomedical technique, which examines the cellular 
processes in a living animal. Near Infrared (NIR) Fluorescence Diffuse Optical Tomography 
(FDOT) is an optical imaging technique in which a fluorescence dye (fluorophore >700 nm) 
is irradiated with near infrared light and the remitted fluorescence collected for imaging. This 
technique has a potential to be of great use in the detection of hypoxia. 
In the near infrared range, human tissue has relatively low absorption and high 
scattering, thus allowing an efficient penetration for near infrared light to pass through the 
tissue.14 With the combination of a hypoxia marker that has the ability to target hypoxic 
regions of the tumor and a fluorescent dye, this technique can provide great sensitivity and 
specificity about the hypoxic regions of the tumor tissue. The signals from a fluorescent dye 
can be detected up to 2 to 3 cm from the skin surface and can be reconstructed in to an image 
to get the insight of the microenvironment of the tumor. Near infrared (NIR) Fluorescence 
Diffuse Optical Tomography (FDOT) is cost effective and has tremendous potential for 
probing tumor molecular markers. 
Indocyanine dyes are an important class of NIR probes, among them indocyanine 
green (ICG, 2) (Figure 1.5) is the only clinically approved dye for imaging purposes. 
Because of its high molar absorptivity and low toxicity, ICG 2 has various applications in 
fluorescence imaging15-18 and it is the only FDA approved dye can be used in humans to 
administer the imaging studies. 
 Figure 
1.4 Indocyanine Green and Nitroim
 The light penetrate through the tissues as a function of wavelength, 
wavelength light absorbs on the surface of the tissue
biological processes that happen in the tissues. The 
underneath the tissue and useful
human tissue are hemoglobin and water, hemoglobin strongly absorbs at wavelengths lower 
than 650 nm and water absorbs strongly at wavelengths higher than 900
window between 650-900 nm i
Figure 1.6. Penetration 
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Indocyanine green (ICG, 2) meets the requirements of an NIR-FDOT dye, it absorbs 
at 760 nm and emits at ~807 nm, ICG has high molar absorptivity (250,000 cm-1 M-1), which 
makes ICG a good contrasting dye to conduct fluorescence imaging deep under the surface of 
the skin. Studies in animals20,21 and humans22,23 have demonstrated that ICG has the ability to 
enhance contrast in tumor imaging. However, there are limitations to the use of ICG, 2 as a 
contrasting agent; it is highly non-specific, binds to plasma proteins, quickly washes out of 
the body and tumor site, the photostability in aqueous medium is low, and it has a low 
quantum yield.24,25 These issues can be resolved with a dye that can target tumors 
specifically, and can be retained in the body for longer durations of time. 
Hypoxic regions in tumors can be targeted with 2-nitroimidazoles. These compounds 
have a high affinity and sensitivity towards hypoxic cells. The sensitivity towards hypoxic 
cells is due to an enzyme-mediated four-electron reduction, which accumulates the 
nitroimidazoles in hypoxic regions of a tumor. A P-450 reductase is responsible for the  
reduction of nitroimidazoles, the actual mechanism for the nitro reduction is not known but 
the outline of a plausible mechanism is shown in Scheme 1-1.26,27 Oxygen in normal tissue 
quickly reverses the reduction of nitroimidazoles, which prevents the congregation of 
reduced nitroimidazoles and blocks the reduction of nitroimidazoles. This observation 
accounts for the increase in sensitivity of nitroimidazoles towards hypoxic cells. Eventually 
these reduced nitroimidazoles bind with macromolecules and are retained in the hypoxic 
regions.28,29 Low oxygen levels in hypoxic regions produces less hydroxyl radicals, which 
limits the effectiveness of radiation therapy. However, the effectiveness of radiation therapy 
can be increased by utilizing radiosensitizers that mimics the hydroxyl radicals. 
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Nitroimidazoles are known bioactive radiosensitizers that makes tumor cells more sensitive 
to radiation therapy.30 
N
NR
NO2
N
NR
NHOH
HN
NR
NH2
P450 reductase; -4e-
N
NR
NH
HO
H2O
 
Scheme 1-1. Plausible mechanism for the reduction of nitroimidazoles 
Among the members of nitroimidazole family, metronidazole (3) was the first one 
discovered in the late 1950’s. It was used as an antibiotic initially and also as amebicide and 
antiprotozoal. Other members of this family are 5-nitroimidazole containing compounds 
tinidazole (4), and ornidazole (5), both have been serving effectively as antiprotozoal drugs.30 
(Figure 1.7) 
 
Figure 1.7. Structures of 5-nitroimidazoles: metronidazole, tinidazole, and ornidazole  
Metronidazole acts as a hypoxic sensitizer at higher doses.31 Studies have shown that 
among other nitroimidazoles such as misonidazole (6),31 pimonidazol (7),32 and etanidazole 
(8),33 (Figure 1.8) 2-nitroimidazoles are effective sensitizers, and have low cytotoxicity. 
Etanidazole (8) is of great interest because it is less toxic compared to other compounds of 
the family.33 
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Figure 1.8. Structures of 2-nitroimidazoles: misonidazole, pimonidazole, and etanidazole 
 If nitroimidazoles can couple to indocyanine green dye, it would provide a method to 
target and image hypoxia in tumor cells. Since ICG (2) lacks reactive functional groups to 
couple nitroimidazoles, a chemical modification is needed in order to functionalize ICG (2) 
(Figure 1.10). This problem was solved by using a structural analogue of ICG (2) called ICG 
bis-carboxylic acid (9).34 (Figure 1.9)  
N
N
N
N
LINKERLINKER ICG BISCARBOXYLIC ACID
O O
NO2
O2N
 
Figure 1.9. Design of hypoxia targeting dye conjugates 
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Figure 1.10. Structure of ICG bis-carboxylic acid (9) 
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Independent contributions from Lindsey et.al.;34 Ozinskas et al.;35 Licha et al.;36 and 
Smith et al.;24 have provided synthetic routes for the synthesis of the ICG bis-carboxylic 
acid (9).  The Smith group has also developed a method for coupling nitroimidazoles to ICG 
bis-carboxylic acid (9), and the resulting dyes were labeled as “first generation dye 
conjugates”. In the first generation dye conjugates, the nitroimidazole moiety and ICG bis-
carboxylic acid were connected by an ethanolamine linker 10a, 10b (Figure 1.11).24,37 
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O N
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X
Y
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Figure 1.11. Structure of 2-nitroethanolamine ICG dye conjugates 
The same strategy was applied to make piperazine analogs 26a, 26b with piperazine 
as a linker instead of ethanolamine and the resulting dye conjugates are labelled as “second 
generation dye conjugates”. It was believed that piperazine analogue would have a longer 
lifetime in the mice relative to ethanolamine dye conjugates 10a, 10b because of the stable 
amide bonds, which are less susceptible to hydrolysis. The ICG bis-carboxylic acid (9) has a 
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slightly higher extinction coefficient and quantum yield than the commercially available ICG 
(2) however there is room for the development of photophysical properties of ICG bis-
carboxylic acid (9) (Table 1-1). In the “third generation”, attempts were made to improve the 
photophysical properities of ICG bis-carboxylic acid (9). Our approach was to introduce a 
ring system into the polyene chain so that it increases rigidity in the molecule and thereby 
increasing the quantum yield.  
Table 1-1. Photophysical properties of indocyanine green dyes 
Dye λabs (nm) λem (nm) 
Extinction 
Coefficient, ε 
(M-1cm-1) 
Quantum 
Yield (ɸ) 
FDA approved ICG (2) 779 807 115,000 0.012 
ICG bis-carboxylic acid (9) 754 778 211,000 0.066 
2-Nitroimidazole-ethanolamine-ICG (10a) 756 779 205,222 0.066 
4-Nitroimidazole-ethanolamine-ICG (10b) 755 779 207,519 0.054 
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Chapter 2.  
SYNTHESIS, PHOTOPHYSICAL CHARACTERIZATION AND HYPOXIA 
EVALUATION OF FIRST GENERATION DYE CONJUGATES 
(NITROIMIDAZOLE-ETHANOLAMINE-ICG DYE CONJUGATES) 
2.1 ICG biscarboxylic acid and its synthesis 
The bioreduction of nitroimidazoles is responsible for selective cytotoxicity towards 
the cells in the hypoxic regions.38 As a result of anaerobic enzymatic reduction, 
nitroimidazole containing compounds generate cytotoxic metabolites. In order to develop a 
hypoxia tumor probe that could be examined, it is very important to verify (i) a 
nitroimidazole moiety can be coupled to ICG bis-carboxylic acid and (ii) examine that the 
new dye-conjugate retains the useful photophysical properties for NIR fluorescence imaging. 
Commercially available ICG (2) has weak fluorescent properties, and it has no functional 
groups to couple nitroimidazole moiety to target hypoxia. Therefore, we chose ICG bis-
carboxylic acid (9) as the prototype dye. A modified version of ICG was made with 
carboxylic acid groups, ICG bis-carboxylic acid. Photophysical properties of ICG bis-
carboxylic acid are within the required range and better than commercial ICG (Table 1-1). 
The increase in quantum yield of ICG bis-carboxylic acid could be due to the suppression in 
the formation of fluorescence-quenched aggregates.39,40 A straightforward synthesis of (9) 
was reported by Lindsey and co-workers (Scheme 2-1),41 in which the reaction of p-
hydrazinobenzoic acid (11) with 3-methyl-2-butanone gave a 68% yield of 12, via a Fischer 
indole synthesis. Subsequent treatment with butanesultone gave a 32% yield of 13. Ozinskas 
and co-workers prepared 12 by a similar route, in 98% yield.41 In this later case, treatment of 
12 with ethyl iodide at 120 °C in a sealed tube gave the corresponding alkylated product in 
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26% yield, and heating with butanesultone at 180 °C gave 13 in 88% yield.42 Licha et al. 
prepared 9 by a similar route.39 In all cases the dyes were assembled by condensation of 13 
with the commercially available glutacondianil hydrochloride (14).39,41,43 
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S O
O O
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N
HOOC
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NHOOC
SO3
N COOH
NaO3S
NaOAc
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86%
11 12 13
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9
 
Scheme 2-1. Synthesis of ICG bis-carboxylic acid (9) 
It is noted that the synthesis of 9 may lead to a mixture of stereoisomers due to 
rotation about each of the four C-C single bonds of the polyene unit. As seen in Figure 2.1, 
the HPLC trace for 2, there is a clear indication that this compound is a mixture of 
stereoisomers. We can find no instance in the literature where a similar stereochemical 
analysis was reported in connection for a study. Our analysis of synthetic 9 in Figure 2.2, on 
the other hand, shows two peaks, indicating there are fewer stereoisomers when compared 
with the HPLC trace of 2.  
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Figure 2.1. HPLC of commercial ICG 2 
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Figure 2.2. HPLC of ICG bis-carboxylic acid (9) 
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Many polyenes exist as the lower energy all-E isomer, but solvent effects as well as 
structural features of the molecule can stabilize other isomers, leading to mixtures.44-46 The 
major stereoisomer of 9 may be the all-E isomer, but we have no evidence to absolutely rule 
out other isomers. It is clear, however, that ICG bis-carboxylic acid (9) is relatively pure 
when compared to compound commercial ICG (2). The dyes used in our study are bis-
carboxylic acid derivatives, prepared in a manner identical to 9, and we believe the 
stereochemistry of all dyes is similar to 9. However, the compounds we have prepared, as 
well as those similar compounds reported in the literature, are probably not a single isomer, 
and isomers would arise from isomerization associated with the polyene linker. The 
interactions of the polar substituents incorporated into these dyes may lead to stabilization 
and the relatively small mixture of observed isomers. 
2.2 Synthesis of first generation dye conjugates (nitroimidazole-ethanolamine-
ICG) 
Nitroimidazole moieties were prepared from the corresponding nitroimidazoles. 
Synthesis began by treating nitroimidazoles (15) with bromomethyl acetate to get the 
corresponding nitroimidazole acetates 16(a), 16(b), which were subsequently treated with 
ethanolamine to get the ethanolamine derivatives 17(a), 17(b) (Scheme 2-2). Initial 
experiments attempted to couple the ethanolamine unit to the hydrazinobenzoic acid (11), but 
gave little or no yield of the desired coupled product. The targeted nitroimidazole-dye 
conjugates were prepared by combining the nitroimidazole fragments 17a, 17b with the ICG 
bis-carboxylic acid (9) in presence of PyBop, hydroxybenzotriazole (HOBt) and 
diisopropylethylamine (DIPEA). We prepared 4-nitro and 2-nitroimidazole ethanolamine 
fragments, 17(a) in 60% yield, 17(b) in 90% yield. Using PyBop as a coupling agent, ICG 
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bis-carboxylic acid was coupled to nitroimidazole ethanolamine fragments to get 2-
nitroimidazole ethanolamine dye conjugate, 10a in 25% yield and 4-nitroimidazole 
ethanolamine dye conjugate, 10b in 20% yield. 
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Scheme 2-2. Synthesis of nitroimidazole-ethanolamine-ICG dye conjugates.  
Reaction Conditions: (a) bromomethyl acetate,TBAI, K2CO3, CH3CN, 80 °C, 45 min (b) 
Methanol, ethanolamine, r.t., overnight (c) DMF, PyBOP, DIPEA, HOBt, 17a, 17b, 0 °C-r.t., 
48 h. 
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2.3 Photophysical properties of first generation dye conjugates 
Photophysical properties of indocyanine green bis-carboxylic acid (9), and 
ethanolamine linked nitroimidazole conjugates 10a, 10b were measured using an UV-VIS 
spectrophotometer and a fluorescence spectrophotometer (Varian Analytical Instruments, 
Walnut Creek, CA). The wavelength range of both spectrophotometers is 250 nm-1100 nm. 
Dye solutions were made by dissolving dyes in Phosphate Buffer Saline (1×PBS) and the 
absorption and fluorescence spectra were recorded. The normalized absorption and 
fluorescence spectra of 1 mM solution of bis-carboxylic acid ICG (9) are shown in Figure 
2.3.  
 
Figure 2.3. Absorption and fluorescence spectra of ICG bis-carboxylic acid 
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Table 2-1. Photophysical properties of nitroimidazole-ethanolamine-ICG dye conjugates 
Dye λabs (nm) 
λem 
(nm) 
Extinction Coefficient, ε 
(M-1cm-1) 
Quantum 
Yield 
(ɸ) 
FDA approved ICG 
(2) 780 807 115,000 0.0120 
ICG bis-carboxylic 
acid (9) 755 790 221,000 0.0728 
2-Nitroimidazole-
ethanolamine-ICG dye 
conjugate (10a) 
760 790 159,000 0.0420 
4-Nitroimidazole-
ethanolamine-ICG dye 
conjugate (10b) 
755 779 208,000 0.054 
The results of photophysical characterization of 9, 10a, and 10b in Phosphate Buffer 
Saline (PBS), are shown in Table 2-1, with absorbance peaks at 754-756 nm and 
fluorescence peaks at 778-779nm. Dye conjugates and ICG bis-carboxylic acid showed a 
blue shift of 25 nm in the absorption and 30 nm shifts in the fluorescence compared to FDA 
approved ICG (2). There is no significant change between the ICG bis-carboxylic acid (9) 
and the ethanolamine dye conjugates in the absorption and fluorescence spectral profiles. The 
extinction coefficients are 1.9 times higher than that of FDA approved ICG (2). The relative 
quantum yields are calculated using commercial ICG (2) as a standard.39 The relative 
quantum yields of the new compounds are 4.5-6 times higher than that of FDA approved ICG 
(2). The fluorescence quantum yield of 9 (0.066) is slightly higher than the FDA approved 
ICG (0.012), probably due to the observation that formation of fluorescence-quenched 
aggregates is suppressed because dye-dye interaction and aggregation is reduced by 
hydrophilic, non-charged but sterically demanding substituents.39,40Among all the imidazole 
ethanolamine conjugates, 2-nitroimidazole ICG, 10a has the highest quantum yield. The 
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ability of targeting hypoxic regions in cancer cells depends on the oxygen concentration at 
which bioreductive trapping happens and the enzyme activity in bioreductive activation.47 As 
mentioned earlier, nitroimidazoles are selectively reduced by nitroreductase enzymes under 
hypoxic conditions to form reactive products that can bind to cellular nucleophiles.48 Because 
10a has a higher reduction potential and a highest quantum yield, it was selected for the in-
vivo hypoxia evaluation. 
2.4 FDOT System and Tumor Imaging 
The in vivo experiments were performed using a frequency domain fluorescence 
imaging system (Figure 2.4), developed by Prof. Quing Zhu in the engineering department at 
the University of Connecticut. The system consisted of 14 parallel detectors and 4 laser 
diodes of 690, 780, 808, and 830 nm. Each laser diode was sequentially switched to nine 
positions on a hand-held probe. The excitation wavelength used in this study was 690 nm. 
The 14-channel parallel detection system has two modes: fluorescence mode and absorption 
mode. The two modes can be easily switched by moving a mechanical handle. A stopper was 
designed in the system to ensure a precise optical collimation when switching between these 
two modes. Note that in the fluorescence mode, a bandpass filter was placed in the light path 
to remove the excitation and stray light; in the absorption mode, the bandpass filter was 
moved out of the light path. Fourteen photomultiplier tubes were used as detectors, and the 
received signals were amplified by preamplifiers, mixed by mixers, low pass filtered, and 
further amplified before analog to digital converters. Two National Instrument data 
acquisition cards of eight channels each were used to acquire FDOT data. 
 Figure 2
The tumor was imaged for up to 1 min post injection and again at 15 min, 30 min, 1, 
2, 3, 5, and 7 h. The center of the probe was aligned to the center of the tumor and the 
separation between the tumor 
for fluorescence images. Several imaging data sets were collected to compare the in vivo 
imaging sensitivity of two hypoxia dye conjugates versus ICG
different concentrations and tumors located at different depths.
To validate the in vivo FDOT imaging results, excised tumor samples were imaged 
using a commercially available Odyssey Imaging system (Li
Using this system, 10 µm tumor sample sect
resolution available (i.e., 21 µ
was 820 nm with a bandwidth of 40 to 50
software provided by the comp
tumor sample area was measured using Image
done in Dr. Quing zhu’s lab by her graduate students.
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center and the probe surface was defined as the imaging
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-COR Biosciences, Nebraska). 
ions were dried and imaged at the highest scan 
m). The excitation channel selected was 785 
 nm. The images were obtained using the analysis 
any. The mean pixel value of the images including the entire 
 J software. These in vivo experiments were 
  
 
 
49
  
 depth 
(9) at 
nm and emission 
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Figure 2.5, shows the fluorescence images obtained by FDOT of the mice mice 
injected with 25 µM ICG bis-carboxylic acid 9 and Figure 2.6, shows 25 µM 2-
nitroimidazole-ethanolamine-ICG 10a. These images are obtained over 5 to 7 h period. Each 
image is 9 cm  × 9 cm in x and y spatial dimensions at the corresponding target depth and the 
color bar represents the reconstructed dye concentration in µM.  
Figure 2.5. Tumor images of mice injected with 25 µM ICG bis-carboxylic acid (9) 
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Figure 2.6. Tumor images of mice injected with 25 µM 2-nitroimidazole-ethanolamine-ICG 
dye conjugate (10a) 49 
ICG bis-carboxylic acid (9) was completely washed out after 3 h and the maximum 
fluorescence concentrations obtained from reconstructed images at 1, 15, 30, 60, 120, 180, 
and 300 min post injection were 0.044, 0.066, 0.078, 0.033, 0.029 0.025, and 0.000 µM, 
respectively, after subtraction of background value of 0.06 µM. However, for targeted 
conjugates, the maximum fluorescence concentrations measured post injection of 25 µM 
ethanolamine-2-nitroimidazole-ICG were 0.028, 0.037, 0.041, 0.037, 0.036, 0.032, 0.026, 
and 0.025 µM above the background. We are gratified to see that the 2-nitroethanolamine 
dye conjugate was retained up to 7 h, whereas ICG bis-carboxylic acid acid was washed out 
in 3 h. 
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Chapter 3.  
SYNTHESIS, PHOTOPHYSICAL CHARACTERIZATION AND HYPOXIA 
EVALUATION OF SECOND GENERATION DYE CONJUGATES 
(NITROIMIDAZOLE-PIPERAZINE-ICG DYE CONJUGATES) 
3.1 Synthesis of second generation dye conjugates 
To further improve the retention time of the dye conjugate, the second generation dye 
conjugate was designed and synthesized. The ethanolamine linker was replaced with a 
piperazine linker in the second generation dye. This modification was based on two 
assumptions; (a) amide bonds are less susceptible to hydrolysis compared to ester bonds and 
(b) the bioavailability of the dye conjugate should increase by the presence of piperazine 
moiety. Since 2-nitroimidazole (15a) is very expensive chemical, 4-nitroimidazole was 
chosen to optimize the reaction conditions for the synthesis of nitroimidazole piperazine 
moiety (25). 
4-Nitroimidazole acetate (16b) was prepared by treating 4-nitroimidazole (15b) with 
bromomethyl acetate, which was hydrolyzed to the corresponding acid (18) by simple 
refluxing in water (Scheme 3-1). In this reaction water acted as nucleophile to hydrolyze the 
methyl ester, we thought piperazine is a good nucleophile compared to water, so 16b reflux 
with piperazine in water should provide the coupled product 19 (Scheme 3-2). Our attempt to 
couple 4-nitroimidazole methylacetate (16b) with piperazine gave a white solid. The melting 
point of the white solid was different than either of the starting materials, broad acid peak 
was absent in the IR spectrum. The HRMS was matched with the desired product mass, the 
13C showed the correct number of carbons, and proton NMR was consistent and matched 
with the proton count except the splitting pattern of piperazine protons. Based on the above 
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observations, we determined that we obtained the coupled product 19, but the NMR splitting 
of piperazine protons peak was not convincing. Another possibility was formation of a salt of 
starting material. The solution to this puzzle lay in identifying the bond between piperazine 
and nitroimidazole fragment as covalent or ionic? We initiated 2D NMR experiments, and 
there was no correlation between the carbonyl and the piperazine carbon atoms in HMBC. 
This information along with the NMR splitting pattern showed that the product was not 
formed but rather a salt of starting material 20. Careful examination of the starting material, 
suggests that salt formation is reasonable, because fragment 18 is a substituted acetic acid, 
and piperazine is a base containing a nitrogen atom (Scheme 3-1). Based on this experiment, 
we changed the synthetic route (Scheme 3-3). Piperazine was protected with Boc and treated 
with bromoacetyl bromide to give key intermediate 23, which was coupled to nitroimidazole 
to give intermediate 24. The boc group was removed by TFA and attempts to recover the 
product as a free base 19 were failed. And there were issues with the product going into 
aqueous layer during the work up. To overcome this issue, we bypassed the workup and 
obtained the product 25 as a TFA salt. 
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Scheme 3-1 Nitroimidazole methylacetate (16b) hydrolysis 
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Scheme 3-2. Piperazine coupling to nitroimidazole methylacetate (16b) 
The successful synthesis was began with piperazine, Boc protected piperazine 22 was 
prepared in 35% yield using a literature procedure.50 Subsequent treatment of 22 with 
bromoacetyl bromide gave compound 23 in 81% yield, and subsequent coupling to 2-
nitroimidazole gave compound 24a, in 94% and 24b in 90% yield (Scheme 3-3).  
Removal of Boc group with trifluoroacetic acid gave trifluoroacetyl salt 25a (76% 
yield) and 25b (86% yield). These TFA salts were coupled to ICG bis-carboxylic acid (9) by 
the same coupling procedure used to prepare compound 10a and 10b,51 giving 
2-nitroimidazole-piperazine-ICG, 26a in 20% yield, and 4-nitroimidazole-piperazine-ICG, 
26b in 25% yield (Scheme 3-4).  
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Scheme 3-3. Synthesis of nitroimidazole piperazine fragments.  
Reaction Conditions: (a) CH2Cl2, (Boc)2, 0 oC-r.t., 16 h, 35% (b) Et3N, bromoacetyl bromide, 
r.t., overnight, 81% (c) NaH, DMF, 23, 0 oC-r.t., overnight (d) TFA, CHCl3, overnight. 
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Scheme 3-4. Synthesis of nitroimidazole-piperazine-ICG dye conjugates.  
Reaction Conditions: (e) DMF, PyBOP, DIPEA, HOBt, 25a or 25b, 0 °C-r.t., 48 h. 
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We considered ICG bis-carboxylic acid 9 as our standard in our first generation, 
however keeping in mind the structural features of second generation dye conjugates, 
imidazole-piperazine-ICG (31) would make the better standard rather than ICG bis-
carboxylic acid (9). We wanted to synthesize imidazole-piperazine-ICG (31) and test against 
the second generation dyes. The synthesis of imidazole piperazine fragment 29 was not 
straightforward. Our initial attempt with NaH in DMF overnight, gave the 1,3-di-subustituted 
imidazolinium salt 28 (Scheme 3-5). Overnight stirring in DMF at room temperature also led 
to the di-substituted salt, 28. We tried the reaction in acetonitrile with K2CO3 at 45 °C which 
gave the same di-substituted salt 28 as the product. The stoichiometric ratios of the reactants 
were modified but could not change the reaction outcome. It is conceivable that nitro groups 
on imidazole ring lower the nucleophilicity of the other nitrogen atom in the ring, thus 
allowing the mono substitution as favorable process in case of nitroimidazoles. We were able 
to get mono substituted product as a major product by stirring the reactants in acetone/K2CO3 
at room temperature for 4 h or DMF/NaH at room temperature for 2 h. 
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Scheme 3-5. Synthesis of imidazole piperazine fragment 
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Scheme 3-6. Synthesis of imidazole-piperazine-ICG dye conjugate 
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The mixture of mono and disubstituted products was purified by column 
chromatography to obtain the pure imidazole piperazine fragment. Removal of boc and 
coupling with ICG bis-carboxylic acid proceeded smoothly to give the imidazole-piperazine-
ICG dye conjugate (31) (Scheme 3-6). 
3.2 Photophysical properties of second generation dye conjugates 
The 2-nitroimidazole-piperazine-ICG (26a), 2-nitroimidazole-ethanolamine-ICG 
(10a), and ICG bis-carboxylic acid (9) were spectrally characterized by using a UV-Vis 
spectrophotometer and a fluorescence spectrophotometer (Table 3-1)(Varian Analytical 
Instruments, Walnut Creek, California). The wavelength range of both spectrophotometers is 
250 nm to 1100 nm. The relative quantum yield of each dye was calculated according to the 
following equation. 
      	
	
 



 
The term Grad was the gradient or slope from the plot of the integrated fluorescence 
intensity versus absorbance measured at different concentrations, x is any unknown dye, STD 
is the standard dye, and η is the refractive index of the solvent. 
Table 3-1. The optical properties of ICG from Sigma-Aldrich, ICG bis-carboxylic 
acid, 2-nitroimidazole-ethanolamine-ICG, and 2-nitroimidazole-piperazine-ICG. 
Dye λabs (nm)a λem (nm) Extinction Coefficient, ε (M-1 cm-1) 
Quantum 
Yield 
(ɸ) 
FDA approved ICG 
(Sigma Aldrich) 780 807 115,000 0.0120 
ICG bis-carboxylic acid 
(9) 755 790 221,000 0.0728 
2-Nitroimidazole-
ethanolamine-ICG (10a) 760 790 159,000 0.0420 
2-Nitroimidazole-
piperazine-ICG (26a) 760 790 230,000 0.0825 
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a
 λmax abs is the wavelength measured at the maximum absorption spectrum, and λmax 
ems is the wavelength measured at the maximum emission spectrum. 
 
Figure 3.1. (a) Absorbance spectra of 2-nitroimidazole-piperazine-ICG (26a), 2-
nitroimidazole-ethanolamine-ICG (10a), ICG bis-carboxylic acid (9), and FDA approved 
ICG (2). (b) Corresponding fluorescence emission intensity versus wavelength measured at 
the excitation wavelength of 730 nm. All the samples were in 2.35 µM concentration. 
3.3 Hypoxia evaluation  
After the synthesis was complete, the second-generation dye conjugate was tested in 
the mice. Fluorescence tomography images were collected over 5-7 h period.  As expected 
the second-generation dye conjugate fluorescent signals were much more intense, when 
compared to the first-generation dye conjugates. As seen from the images (Figure 3.4), the 
signal intensity of second-generation piperazine dye conjugates improved 2.5 to 3 times 
during the first 3h post injection period and 1.8 times after 3 h post injection than the first 
generation ethanolamine dye conjugates (Figure 3.3). ICG was washed out with in the first 
3 h (Figure 3.2). The signal intensity of both first-generation and second-generation dye 
conjugates 10a, 26a is strong compared to ICG bis-carboxylic acid (9), between the first and 
second generation, the sensitivity of the signal is substantially improved with the second 
generation dye, 26a. The FDOT images of mouse tumor are shown in the following figures. 
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Figure 3.2. Mouse tumor images (~10 mm tumor size) injected with 25 µM ICG bis-
carboxylic acid (9) 
 
Figure 3.3. Mouse tumor images (~8 mm tumor) injected with 25 µM 2-nitroimidazole- 
ethanolamine-ICG (10a) 
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Figure 3.4. Images of a mouse tumor (~8 mm tumor) injected with 25 µM 2-nitroimidazole-
piperazine-ICG (26a) 
 
Figure 3.5. Images of a mouse tumor (~8 mm tumor) injected with 15 µM 2-nitroimidazole-
piperazine-ICG (26a) 49 
30 minutes 1 hour
Time after 25 uM 2-Nitroimidazole-ICG-p injection
15 minutes1 minute
5 hours3 hours2 hours 7 hours
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
0.14
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
0.14
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
0.14
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
0
2
0.06
0.08
0.1
0.12
0.14
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
0.14
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
0.14
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
0.14
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
0
2
0.06
0.08
0.1
0.12
0.14
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
30 minutes 1 hour
Time after 15 uM 2-Nitroimidazole-ICG-p injection
15 minutes1 minute
5 hours3 hours2 hours 7 hours
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
0
2
0.06
0.08
0.1
0.12
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
X (cm)
Y 
(cm
)
 
 
-2 0 2
-2
-1
0
1
2
0.06
0.08
0.1
0.12
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Y 
(cm
)
Chapter 3. Second generation dye conjugates 
35 
 
The sensitivity of 2-nitroimidazole-piperazine-ICG-dye (26a) conjugate was further 
tested by using a 25 µM concentration for injection. A mouse with 10 mm size tumor was 
injected with 25 µM solution of piperazine dye conjugate and the fluorescence tomography 
images were collected over 24 h. This experiment showed the fluorescence signals even at 
24 h. 
One method to improve tumor imaging is to improve the bioavailability 52 of the dye 
conjugate. A piperazine unit is common in many drugs,53 which was the reason we chose a 
piperazine linker, with the goal of increasing bioavailability54 of the dye conjugate. We do 
not believe that the piperazine per se exhibits any influence on the hypoxia targeting. 
However, if the bioavailability of the dye conjugates leads to a greater concentration in the 
tumor, presumably, enzymatic reduction of the nitro group will lead to an increased 
concentration of the dye conjugate. We believe that the observed greater distribution of 2-
nitroimidazole-piperazine-ICG in tissues may be due to the larger number of carbon atoms 
and slightly diminished polarity, which increases solubility in tissue when compared to the 2-
nitroimidazole-ethanolamine-ICG. Increased solubility would lead to a greater percentage of 
dye reaching the tumor, along with other tissues; however, selective hypoxia binding of the 
dye should lead to a larger percentage of dye conjugate in the tumor relative to other tissues, 
which would be measured as greater long-lasting fluorescence intensity. Mice experiments 
were done by Saeid, a graduate student in Dr. Quing Zhu’s group. Indeed, they have 
observed increased fluorescence intensity of excised mouse tissues, such as liver and kidney, 
injected with 2-nitromidazole-piperazine-ICG as compared with the tissues injected with 2-
nitroimidazole- ethanolamine-ICG, as well as enhanced tumor imaging. 2-nitroimidazole 
compounds are reduced in hypoxic cells and irreversibly bind to macromolecules (protein, 
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nucleotides, etc). The bound compounds would remain until cell metabolism removed the 
macromolecules. It is well documented that the stability and half-life of the compound in the 
cells are dependent on cell type.55 Different researchers have observed the turnover rates of 
hypoxic tumor cells with half-lives ranging from 17 to 49 h in various solid tumors. Due to 
animal study constraints, we did not image every mouse beyond 7 h, except for one. As 
shown in Figure 3.6, the fluorescence image obtained at 24 h is about the same level as that 
obtained at 3 h, which suggests that the optimal window to image hypoxia condition of the 
tumor is at least between 3 to 24 h. 
 
Figure 3.6. Tumor images injected with 25µM 2-nitroimidazole-piperazine-ICG dye 
conjugate 26a 49 
Animals were sacrificed and immunohistochemistry (IHC) was performed on the 
tumor slices and the hypoxic regions were stained brown. All experiments involving animals 
were done by our collaborator, Dr. Quing Zhu.49 Two areas of higher and lower fluorescence 
intensity in each Li-Cor images were selected to compare the corresponding hypoxic areas in 
IHC images. Within each image the higher and lower signal intensity areas correspond to 
higher (more brown stains) and lower (less brown stains) hypoxic areas. 
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 Figure 3.7. The corresponding ex 
Imaging system of (a) mouse image injected with 25 
mouse image injected with 25 
corresponding images of two mice 
ICG (26a) , respectively, (e) through (h) corresponding IHC stains (40×, brown) at low tumor 
hypoxic area as marked at corresponding images, (m) through (p) corresponding IHC stains 
(40×) at higher hypoxic area, (i) through (l) corresponding IHC stains at low hypoxic area 
(400×, brown), and (q) through (t) corresponding stains at higher hypoxic area.
A group of mice were injected with 25 
piperazine-ICG and fluorescence was measured in tumors located at different depths. 
Statistics of reconstructed fluorescence (concentration vs. time) of ICG and 2
piperazine-ICG were shown in 
minutes and the vertical axis is the re
µM. The dye concentration injected was 25 
nitroimidazole-piperazine-ICG (red) with tumor located at 1.5 cm and (b) 2 cm.
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Figure 3.8. Statistics of reconstructed fluorescence of 25 µM ICG and 2-nitroimidazole-
piperazine-ICG with tumors located at 1.5 cm depth 
 
Figure 3.9. Statistics of reconstructed fluorescence of 25 µM ICG and 2-nitroimidazole-
piperazine-ICG with tumors located at 2.0 cm depth 
A group of two mice were injected with 50 µM solutions of ICG, 2-nitroimidazole-
ethanolamine-ICG (10a) and 2-nitroimidazole-piperazine-ICG (26a) and the resconstructed 
fluorescence was plotted against time in minutes. The piperazine analog has a strong signal 
compared to ethanolamine analog; the statistical data is shown in Figure 3.10. 
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Figure 3.10.Comparison of reconstructed fluorescence concentration (maximum) vs. time 
(minutes) of 50 µM ICG (9), 2-nitroimidazole-ethanolamine-ICG (10a) and 2-
nitroimidazole-piperazine-ICG (26a) with tumor center located at 1.5 cm.  
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Chapter 4.  
SYNTHESIS, PHOTOPHYSICAL CHARACTERIZATION AND HYPOXIA 
EVALUATION OF THIRD GENERATION DYE CONJUGATES 
(NITROIMIDAZOLE-PIPERAZINE-RIGID ICG DYE CONJUGATES) 
In an attempt to improve the targeting capability of the dye, as it affects NIR imaging 
of cancerous tumors, we attached a cancer targeting 2-nitroimidazole moiety to the 
fluorescent dye in order to improve detection of the tumor. We prepared bis-carboxylic acid 
ICG (9) using literature procedures, and used it to synthesize dye-conjugates 10a, 10b, 26 by 
linking 2-nitroimidazole acetate units to the dye via ethanolamine and piperazine  linkers.56,57 
The purpose of this research was and is to develop a noninvasive probe for the detection of 
cancerous tumors using NIR fluorescent dyes that contain a nitroimidazole moiety which is 
known to target hypoxic tumors.56,58 The quantum yield for the first and second generation 
dyes used in the study was about 0.06, which was sufficient for the NIR detection of hypoxic 
cancerous tumors in vivo.56 
In our third generation, to further develop this work, we targeted the synthesis of dyes 
with a larger quantum yield with the goal of increasing the sensitivity of our tumor detection 
system. However, any structural changes should retain the emission/absorption wavelengths 
in the NIR region. Once the synthetic work was completed, the next step was to examine 
parameters that influence the fluorescent yield of the dye, without significant perturbation of 
the emission and absorption wavelengths. It is known that conversion of a non-planar 
molecule to a similar but more planar and rigid molecule often leads to an increase in the 
quantum yield of fluorescence.59 Decreases in fluorescence may be associated with a higher 
collisional probability observed with molecules that have a high degree of flexibility. In other 
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words, molecules with more rigid structures have a lower probability of collision, which 
leads to a higher fluorescence potential, because the energy absorbed is not lost due to 
molecular vibration or collision. It has been shown, however, that rigidity (maintenance of a 
planar or near planar configuration) in the first excited S1 excited state is more important than 
rigidity in the S0 state.60 One possible structural change that might lead to rigidity is 
incorporation of a ring into the polyene chain, which increases the rigidity and thereby the 
fluorescent quantum yield. Any structural modification of the polyene unit must produce a 
dye with absorption/emission in the NIR region because, our long term goal for any new dye 
is to eventually prepare derivatives for targeting hypoxia in cancerous tumors. In order to 
introduce the rigidity into the polyene chain, we targeted two new structural types: one, 
introducing a ring into the polyene unit and the second type of structurally modification 
shortened the polyene chain by two carbon atoms (pentamethine dye). The first step toward 
that goal requires synthesis of the dye and a study of the chemical and in vitro physical 
properties of the dye. Therefore, initial work involves the chemical synthesis, chemical 
properties, and in vitro stability studies in PBS and sucrose solution, as well as 
emission/absorbance data of the dyes. As part of initial work which, focuses on identifying a 
new dye with improved fluorescent properties, we have started the synthesis of five and six 
membered ring incorporated indocyanine dyes 32 and a pentamethine dye which has two 
carbon atoms less in the polyene chain 71. (Figure 4.1)  
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Figure 4.1.Structures of third generation dyes 
4.1 Synthesis of third generation dye conjugates 
4.1.1 Ring incorporation into the polyene chain of indocyanine green dye: 
Our attempt to introduce a 1, 4 - substituted ring system in to the polyene chain was 
unsuccessful.  
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Scheme 4-1. Retrosynthesis of poly-ene modified indocyanine dye 
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Retrosynthesis for the synthesis of 32 was shown in Scheme 4-1, and the actual 
synthesis was started with a Diels-Alder reaction between Danishefsky’s diene (35) and acryl 
aldehyde (36) shown in Scheme 4-2. The Diels-Alder reaction in toluene gave a black tar like 
product, whereas in dichloromethane at room temperature gave a clear reaction. The Diels-
Alder adduct 37 was obtained in 38% yield after column chromatographic purification. We 
isolated a compound, that wasn’t present in the crude originally, but eluted during the column 
purification. This explains the reason, for the low yield after purification. The isolated 
product was characterized as 2-methoxy-4-oxocyclohexanecarbaldehyde 39. Since silica gel 
is acidic, we rationalize the observation as deprotection of TMS group by silica gel, followed 
by keto-enol tautomerization to provide the substituted cyclohexanone derivative 39 (Figure 
4.2). 
TMSO
OMe
H
O
OMe
CHO
TMSO
Toluene
Dichloromehtane
Black tar like product obtained
38% yield after the column purification
overnight reflux
r.t., 48 h35 36
37
 
Scheme 4-2. Diels-Alder reaction of Danishefsky’s diene with acrylaldehyde 
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Figure 4.2. Rearrangement of Diels-Alder adduct (37) on silica gel 
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To avoid this issue, we bypassed the purification step and deprotected the Diels-Alder 
adduct to give oxocyclohexene carboxaldehyde 34 (Scheme 4-3). Treatment of the Diels-
Adler adduct with 0.1N HCl in dichloromethane gave the oxo-cyclohexene carboxyaldehyde 
34, but upon loading on silica gel it rearranged to a new product 40, which suggests that the 
product is unstable on silica gel. 
O
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0.1N HCl Silica gel
CHO
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37 34 40
 
Scheme 4-3. Preparation of cyclohexenone carboxaldehyde 34 and its rearrangement 
Therefore we treated the compound 37 with 0.1N HCl and aniline to get the bisanilide 33 
directly, as shown in the following Scheme 4-4. 
OMe
CHO
TMSO
1) 0.1N HCl, r.t., 30 min
2) aniline, r.t., overnight
N HN
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37 33 41
 
Scheme 4-4. Attempted synthesis of bisanilide, 33  
Compound 41 was obtained rather than the bisanilide 33. Compound 41 appears to 
exhibits a vinylogous amide resonance (Figure 4.3) which explains why the reaction did not 
proceed further to get the bisanilide, 33. Several reactions that used anilines substituted with 
electron withdrawing groups on them (4-nitro aniline, 2,4-di nitro aniline), and added Lewis 
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acids such as copper triflate, yetterbium triflate to activate the carbonyl group, did not solve 
the problem. 
H
NO H
NO
41 42
 
Figure 4.3. Vinylogous amide type resonance 
To overcome this issue, we modified our synthetic route (Scheme 4-5), to replace 
acryl aldehyde with methyl acrylate. According to new synthetic route, the Diels-Alder 
adduct 44 of 35 and 43 could be treated with DIBAL-H to give the corresponding alcohol 45. 
Subsequent deprotection of TMS group with yetterbium triflate could provide compound 46. 
Treatment of 46 with aniline could provide compound 47, which could be oxidized to 
aldehyde 48. Finally treatment with 4-nitroaniline should provide the desired bisanilide 49.  
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Scheme 4-5. Retrosynthesis of modified synthetic route to six-membered bisanilide 49 
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During the DIBAL reduction step, elimination gave  the product 50, the TMS group 
was removed  with yetterbium triflate to give compound 51, which upon treatment with 4-
nitroaniline gave compound 52, which tautomerized to give the 1, 4- substituted diene 53 in 
35% yield (Figure 4.4).  
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Figure 4.4. Formation of 1,4-substitued diene from diels-alder adduct 44 
We also attempted a condensation reaction between 13 and 40, and the reaction 
yielded a highly hygroscopic solid (Scheme 4-6). 
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Scheme 4-6. Condesation of betaine indolium acid (13) and enone (40) 
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Despite all our efforts we did not obtain the desired product, although we found many 
unexpected transformations during the synthesis. Some of the transformations may be useful 
for making 1,4-disubstituted cyclic dienes for Diels-Alder reactions.  
We attempted to incorporate an aromatic ring into the polyene chain (Figure 4.5); and 
the reactions yielded brick red solids. We were not able to characterize the outcomes of these 
reactions because of solubility issues. 
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Figure 4.5.Condensation of betaine indolium acid (13) with p-phthalaldehyde (54) and 
phthalaldehyde imine 
All our attempts to synthesize diimine 58 were unsuccessful (Figure 4.6), and all the 
reactions yielded the literature reported iminoisoindoline (59). The diimine 58 was never 
isolated as it is so reactive undergoing intramolecular cyclization to form the 
iminoisoindoline.61  
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Figure 4.6. Formation of iminoisoindoline (59) 
We slightly modified our target by changing the position at which the ring is 
incorporated in to the polyene chain. Instead of connecting the ring at 1,4 positions (32), we 
wanted to connect the ring at 1,3 positions (32’) (Figure 4.7). 
HOOC
N
SO
O
O
O
OH
S
NaO
O
O
N
32
N
O3S
HOOC
R
N
SO3Na
COOH
n
32'
1
2
3
4
1
2 3
 
Figure 4.7. Incorporation of the ring at 1,3-positions 
Tung and co-workers reported just such a molecule as a near infrared fluorochrome, in their 
synthesis of compound 67 (reported as compound NIR820).62  
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In earlier work, Reynolds and Drexhage had prepared heptamethine pyrylium dyes 
that contained a ring in the polyene moiety.63 These dyes were relatively unstable and 
exhibited a bathochromic shift. Slominskii et al. prepared a series of dyes containing a 
polyene moiety (methine dyes), including examples with a cyclohexane ring.64,65 It is noted 
that the reaction of 67 with amines produced a new class of NIR amine tricarbocyanine dyes 
with excellent photostability properties.66 Similarly, reaction with amines followed by 
conversion to the corresponding amide produced NIR amide tricarbocyanine dyes that were 
further modified to include lipoic acid residues used for cancer imaging due their ability to 
serve as highly sensitive NIR SERS reporter molecules.67 For our study, we prepared 67 as 
well as several related indocyanine dyes, first with a six- or a five-membered ring 
incorporated into the polyene system 65, 66 and 68, and another derivative with a shorter 
polyene chain 71.  
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Figure 4.8. Polyene modified indocyanine green dyes 
In Tung and coworker’s work, 67 was used for protein labeling experiments and 67 
was coupled to a peptide as an amino acid residue by initial conversion to the NHS activated 
ester.62,68 Human transferrin (Tf) was used as a model protein and coupling of activated 67 
with Tf gave a conjugate that facilitated florescence measurements in PBS solution as well as 
the protein binding studies. Our primary interest was the synthesis of these compounds and 
determination of changes in fluorescent yield as a function of structure, if any. 
Synthesis of ring incorporated indocyanine dyes was begun by making the five- and 
six-membered bisanilides. Methyl and phenyl substituted bisanilides 61, 62 were prepared 
from N-methylformanilide 60, which was prepared by the reaction of N-methylaniline with 
formic acid and sodium formate.69 As shown in (Scheme 4-7), N-methylformanilide was 
treated first with POCl3 and then with methyl cyclohexene. Subsequent reaction with aniline 
hydrochloride gave six-membered methyl bisanilide 61 in 39% yield.70 1-Phenylcyclohexene 
was converted to 62 in 68% yield using an identical procedure.70  
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Scheme 4-7. Synthesis of six-membered methyl and phenyl bisanildes 
The direct treatment of N-methylformanilide with POCl3 in the presence of 
cyclohexanone and aniline hydrochloride led to a 79% yield of 63.70 The identical reaction 
with cyclopentanone led to 64 in 73% yield.71 
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Scheme 4-8. Synthesis of five- and six-membered bisanilides 
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 With these anilides in hand, coupling with indolenium sulfonate 13 was 
accomplished using the standard procedure from our previous work, as shown in(Scheme 
4-9), anilide and indole heated to 120 °C in acetic acid-acetic anhydride, buffered with 
sodium acetate.56 Using this procedure, 61 converted to 65 in 41% yield, 62 to 66 in 37% 
yield, 63 to 67 in 22% yield, and 64 to 68 in 41% yield. As noted earlier, Tung and co-
workers prepared 67 in 67% yield by heating commercially available 63, obtained from 
Aldrich, with 13 in ethanol at reflux for two hours in the presence of sodium acetate.42  
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Scheme 4-9. Synthesis of ring incorporated indocyanine green dyes 
We prepared a single example of the second target type (71, Scheme 4-10), with two 
carbons less in the polyene linker. Reaction of the bis(dimethyl acetal) of propanedial (69) 
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with aniline, in aqueous HCl led to anilide, 70 in 90% yield.72 Subsequent reaction with 
indole 13 under the standard conditions gave a 30% yield of dye 71.  
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Scheme 4-10. Synthesis of pentamethine indocyanine dye 
4.2 Absorption and fluorescence properties:  
All derivatives were characterized using an UV-Vis spectrophotometer and a 
fluorescence spectrophotometer (Varian Analytical Instruments, Walnut Creek, CA). The 
wavelength range of both spectrophotometers is 250 nm to1100 nm. The dyes were 
suspended in either Phosphate Buffer Saline (PBS) or a 9.25% aqueous sucrose solution, and 
the absorption and fluorescence spectra were recorded. These two solvent systems were 
chosen to be compatible with our previously reported in vivo studies with 10, 26 and related 
compounds. Quantum yields were calculated relative to the standard samples that have a 
fixed fluorescence quantum yield value, according to the following equation  
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   Eq. 1 
Where STD = standard and x = unknown, respectively,  is the fluorescence 
quantum yield, Grad is the gradient from the plot of integrated fluorescence intensity versus 
absorbance, and η is the refractive index of the solvent. 
All UV-Vis spectra were recorded on Cary 50 spectrometer and fluorescence spectra 
on a Cary Eclipse. Fluorescence was measured in a 10 mm fluorescence cuvette and sample 
concentrations were maintained below 0.1 absorbance by diluting the stock solutions to the 
corresponding concentrations. All UV absorbance measurements were done with solvent 
background correction, at the concentrations listed in Table 4-1. 
Table 4-1: Dye solutions used for UV-Vis analysis 
Dye in PBS Stock solution concentration in µM 
65 542.7 
66 428.5 
67 354.3 
68 734.1 
71 420.7 
Dye in Ethanol Stock solution concentration in µM 
65 636.5 
66 417.1 
67 728.5 
68 307.7 
71 144.8 
Dye in 9.25% sucrose Stock solution concentration in µM 
65 681.4 
66 731.9 
67 700.2 
68 1202.4 
71 986.2 
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The florescence yield of 65, 66, 67, 68 and 71 were measured in ethanol using Rh101 
as the standard, in PBS and in a 9.25% sucrose solution using 9 as the standard. All results 
are shown in Table 4-2. It is clear that incorporating a ring into the polyene moiety as in 65, 
66, 67 and 68 had little or no effect, or led to a slight decrease in the quantum yield. 
Although each of these derivatives should be more rigid in terms of rotation about the C-C 
bonds of the polyene, the increase in the number of atoms may mitigate any benefits. On the 
other hand, the chain-shortened derivative 71 showed a significant enhancement in the 
quantum yield, with quantum yields ranging from a low of 0.028 to a high of 0.34. Using 
Rh101 as the standard, the dye 71 absorbed at 657 nm and emission was measured at 676 
nm. These values are in the useful range for NIR analysis, although a different filter would be 
required for a NIR analysis using any dye conjugate prepared from 71 that is structurally 
related to 10, 26. Using 9 as a standard, absorbance of 71 was at 655 nm and emission at 
669 nm in PBS, and absorbance at 655 nm and emission at 672 nm in sucrose solution. The 
chloro and methyl derivatives 65 and 67 showed slight shifts in the absorption and emission 
peaks, relative to 9, although 68 showed a peak past 800 nm. However, the emission peaks 
shifted to past 800 nm for 65, 67, and 68 using Rh101 as standard. Using 9 as standard 
emission peaks are past 800 nm for 67 and 68 (Table 4-2). Tung and coworkers reported data 
for 67 in methanol, and reported that 67 absorbs maximally at 790 nm and emits maximally 
at 820 nm in methanol with a molar extinction coefficient of 184,000, and a quantum yield of 
0.08.42 We found that 67 absorbs at 812 nm and emits at 826 nm, in ethanol, with a quantum 
yield of 0.025 and a molar extinction coefficient of 189,000. Our data was reported using 
Rh101 as a standard. Tung used the same method to determine relative fluorescence quantum 
yield, indicating the use of a standard, but that standard was not identified. As seen in Table 
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4-2, phenyl derivative 66 did not show the shifts observed for 67. In all cases, the quantum 
yield was less than 2, although that of phenyl derivative 66 was close to 9. It is clear from our 
results that incorporation of a ring in the polyene chain does not increase the florescence 
yield. While the ring may diminish the number of stereoisomers that arise due to rotation 
about the C-C bonds, any benefit may be offset by the increased number of atoms  
Loss of two carbon atoms from the polyene chain led to a significant increase in 
fluorescent yield for 71. It is not clear why this relatively minor structural change leads to 
such an increase, but one explanation is that the diminished number of C-C bonds leads to 
fewer isomers due to rotation. It is certainly possible that fewer structural isomers can 
account for the increase in florescence yield. It is also possible that bringing the two indole 
moieties closer together may restrict the rotation and lead to an increase in rigidity. At this 
time, our explanation remains speculative.  
Table 4-2. Photophysical properties of rigid dyes 
 
In ethanol, Rh101  
as a standard 
 
Dye λabs (in nm) λem (in nm) Extinction Coefficient (ε)     
(M-1cm-1) 
Φ 
9 759 778 191,000 0.146 
65 783 803 183,000 0.024 
66 775 791 250,000 0.127 
67 796 811 189,000 0.059 
68 820 840 145,000 0.041 
71 657 676 210,000 0.344 
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 In 1× PBS, bis-carboxylic acid (9) as a  
standard 
 
Dye λabs (in nm) λem (in nm) Extinction Coefficient (ε)     
(M-1cm-1) 
Φ 
9 756 778 237,000 0.066 
65 774 791 184,000 0.024 
66 766 779 210,000 0.055 
67 789 802 210,000 0.028 
68 812 826 255,000 0.025 
71 655 669 220,000 0.289 
 
In 9.25% Sucrose, 
bis-carboxylic acid (9) as a standard 
 
Dye λabs (in nm) λem (in nm) Extinction Coefficient (ε)     
(M-1cm-1) 
Φ 
9 755 779 211,000 0.072 
65 776 791 207,000 0.030 
66 767 787 240,000 0.068 
67 790 815 230,000 0.031 
68 813 833 113,000 0.024 
71 655 672 262,000 0.338 
4.3 Optical stability of rigid dyes in solution 
The photostabilities of all dyes prepared for this study were examined in both PBS 
solution and in 9.25% sucrose solution. The dyes were dissolved in PBS solution and 9.25% 
sucrose solution, and the absorbance of each solution was maintained at approximately 0.82. 
Each sample was irradiated under a 500 W halogen lamp, maintained at a distance of 300 
mm, for 14 h. An aqueous solution of sodium nitrite (50.0 g/L) was placed between the 
samples and the lamp to filter the light to less than 400 nm, and also to mitigate heat from the 
lamp. The initial absorbance data was measured and then measurements were carried out 
each hour. As shown in Figure 4.10 (in PBS solution) and Figure 4.9 (in the sucrose 
solution), all dyes that contained a ring, 65, 66, 67, and 68, showed loss of absorbance over 
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the course of three hours. This data stands in sharp contrast to dye 71, which showed 
significantly improved stability in both PBS and in sucrose. It is noted that we also examined 
the stability in ethanol, but unavoidable evaporation of ethanol over the course of the 
experiment led slight changes in concentration and we deemed the data unreliable. This 
experiment was repeated with the same result, so it is not included here. 
 
Figure 4.9. Photostability studies of rigid dyes in 9.25% sucrose solution 
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Figure 4.10. Photostability studies of rigid dyes in 1×PBS solution 
4.4 2-nitroimidazole-piperazine-rigid ICG dye conjugate synthesis 
Among all the polyene modified rigid dyes, pentamethine dye 71 has the highest 
quantum yield; therefore it was further coupled to ICG bis-carboxylic acid 9 to prepare 2-
nitroimidazole-piperazine-rigid dye conjugate 72. The same coupling procedure to make dye 
conjugates such as 10 and 26 was followed to couple the 2-nitroimidazole piperazine 
fragment 18a to rigid dye 71 (Scheme 4-11). Pybop was used as a coupling agent, reaction 
was carried out in DMF and the reaction progress was monitored by TLC. After 48 h, the 
reaction mixture was dried up by blowing air. The crude mixture was washed couple of times 
with acetonitrile and ethyl acetate to remove soluble impurities. The crude solid was purified 
by C18 reversed phase automated flash column chromatography.  
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Scheme 4-11. Synthesis of 2-nitroimidazole-piperazine-rigid-ICG dye conjugate 
Once we obtained the pure coupled product 72, UV-Vis experiments were conducted 
to find out the extinction coefficient and quantum yield. The extinction coefficient of the 
coupled product was found to be 268,000 and the quantum yield in 9.25% sucrose solution 
was determined as 0.232.  
Table 4-3. Photophysical studies of third generation dyes 
S. No Rigid dye λabs (nm) λem (nm) 
Extinction 
Coefficient, ε 
(M-1 cm-1) 
Quantum 
Yield(ɸ) 
1 71 655 672 262,000 0.338 
2 72 653 670 268,000 0.232 
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Both compounds 71 and 72 were submitted for in vivo studies in the mice.  Since the 
emission wavelength for rigid dyes 71 and 72 is towards the low range, Li-Cor images were 
not collected. The signal strength of 2-nitroimidazole piperazine rigid dye conjugate is 
stronger compared to 2-nitroimidazole piperazine ICG dye conjugate. It stayed in the tumor 
for the same period of time. As the signal strength is very strong, it is possible to inject lower 
dye concentrations so that sensitivity would improve to a great extent. 
4.5 Hypoxia evaluation of third generation dye conjugates 
Preliminary hypoxia evaluation results are shown in Figure 4.11. The third generation 
dyes have higher quantum yield than the first and second generation dyes. The enhancement 
in the intensity of fluorescence signal could be because of higher quantum yield. Three dyes, 
rigid bis-carboxylic acid (nontargeted-rigid, 71), 2-nitroimidazole-piperazine-rigid-ICG 
(targeted-rigid, 72) and 2-nitroimidazole-piperazine-ICG (26a) were tested in the mouse as a 
preliminary evaluation.  
 
Figure 4.11. Fluorescence signal intensities of third generation dyes vs second generation 
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 The rigid bis-carboxylic acid 71 and 2-nitroimidazole-piperazine-rigid ICG 72 have 
higher signal intensities than the 2-nitroimidazole-piperazine-ICG dye for the first 120 min 
time period. And then the rigid bis-carboxylic acid 71 signal intensity went down compared 
to the signal intensity of 2-nitroimidazole-piperazine-ICG 26a, whereas the 2-nitroimidazole-
rigid-ICG 72 signals remained as the higher intensity signals in this group of dyes. Though 
there is no 2-nitroimidazole is present in the rigid bis-carboxylic acid, it stayed as much time 
as the 2-nitroimidazole-piperazine-ICG does, the reason for this observation is not clear yet 
but it could be due to the higher quantum yield of the dye. Dyes with the higher the quantum 
yield can produce strong fluorescence signals even at lower concentrations. Further study is 
ongoing to validate the initial data obtained for the third generation dyes. 
4.6 Future work 
We would like to understand the key structural features in dye conjugates that are 
responsible for binding to hypoxic regions. We have designed few analogues to study the 
structure activity relationship. Compound 73 could provide information on role played by 
nitrogen atom in imidazole ring of the dye conjugates. As shown in Scheme 4-12, pyrrole 
methyl acetate 75 was prepared from tetrahydro-2,5-dimethoxy furan 74 and glycine methyl 
ester in 76% yield. Ethanolamine was coupled to pyrrole acetate 75 by simple overnight 
stirring in methanol at room temperature in 93% yield. Pyrrole ethanolamine fragment 76 
will be coupled to ICG bis-carboxylic acid by the same method used to make our final dye 
conjugates to obtain 73. 
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Scheme 4-12. Synthesis of pyrrole-ethanolamine-ICG dye conjugate 73 
Compound 77 could be useful to understand the effect of the group at the second 
position of imidazole ring in the dye conjugates. The 2-methylimidazole piperazine fragment 
79 was prepared from 2-methylimidazole 78 and bromoacetyl piperazine 23 in 69% yield 
(Scheme 4-13). The boc group was removed by trifluoroacetic acid to give the TFA salt 80 in 
91% yield. It will be coupled to ICG bis-carboxylic acid 9 to give 2-methylimidazole-
piperazine-ICG dye conjugate 77. 
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Scheme 4-13. Synthesis of 2-methylimidazole-piperazine-ICG dye conjugate 77 
Compound 81 could be useful for obtaining information about the role played by the 
carbonyl group linked to piperazine in dye conjugates. The carbonyl group of 2-
nitroimidazole piperazine fragment 24a could be reduced by lithium aluminium hydride 
(LAH) to give the reduced product 82. The boc group can be removed by trifluoroacetic acid 
to give the TFA salt 83, which can be coupled to ICG bis-carboxylic acid 9 to give the dye 
conjugate 81 (Scheme 4-14). 
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Scheme 4-14. Synthetic plan for the synthesis of dye 81 
To understand which protein is binding to nitroimidazole dye conjugate, it is 
important to make biotinlated dye conjugates 85. Biotin 84 is very useful in this study 
because it binds to proteins and enables easy purification in order to study the protein. Biotin 
strongly binds to avidin and streptavidin.73 If Biotin can attach to half loaded dye conjugate, 
(Figure 4.12) it would be possible to access the information about the protein that is binding 
with nitroimidazole moiety in the dye conjugate. With the help of avidin beads, biotin 
complexed protein of the hypoxic tumor cells can be separated from other proteins. The 
protein of interest sticks to the avidin beads while others wash through the column of avidin 
beads. If protein is isolated from the beads, it might provide useful information about how 
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and which part of the nitroimidazole piperazine dye conjugate is responsible for binding, 
which may allow to design more specific dye conjugates. The synthetic plan for the 
biotinlated dye conjugate is shown in Scheme 4-15, indolenium methyl ester 88 was made 
from indolinium betaine sulfate 13 or from hydrazine methylbenzoate.74 From indolenium 
methyl ester 88, mono-carboxylic acid ICG 89 (one of the carboxylic groups on ICG bis-
carboxylic acid was protected as methyl ester) was prepared. The mono-carboxylic acid ICG 
89 could be attached to nitroimidazole by reacting with 2-nitroimidazole piperazine fragment 
to give the half loaded ICG dye 90, which could be coupled to biotin-piperazine fragment 87 
to give the biotinlated dye conjugate, 85. 
Biotin (84)
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Figure 4.12: Biotinlated half loaded dye conjugate  
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Scheme 4-15. Synthetic plan for biotinlated dye conjugate 85 synthesis 
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Chapter 5.  
EXPERIMENTAL 
General 
All chemicals were used as received from Aldrich or Acros. All glassware was flame or oven 
dried, and all reactions in organic solvents were performed under a nitrogen atmosphere, 
unless otherwise noted.  All solvents were dried according to standard procedures. THF was 
distilled from sodium benzophenone ketyl, methylene chloride was distilled from calcium 
hydride, and dimethylformamide was vacuum distilled from calcium hydride. Thin-layer 
chromatography was done on Sorbent Technologies aluminum-backed TLC plates with 
fluorescent indicator and 0.2 mm silica gel layer thickness, and p-anisaldehyde, 
Phosphomolybdic acid were used as developing agents. Column chromatography was done 
using 60 Å porosity, 32-63 µm silica gel. 1H and 13C NMR were collected on a Brüker 
Avance 300 (300.13 MHz 1H, 75.48 MHz 13C), Brüker DRX-400 (400.144 MHZ 1H, 100.65 
MHz 13C) or a Brüker Avance 500 (500.13 MHz 1H, 125.65 MHZ 13C). Chemical shifts are 
given in ppm downfield from TMS in the following format chemical shift, multiplicity 
(s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet) coupling constant in Hz and 
Integration. Photophysical properities of dyes were found on UV-Vis spectrophotometer and 
a fluorescence spectrophotometer (Varian Analytical Instruments Walnut Creek, California). 
Mass spectroscopy data was collected on a HP 5870B GC/MSD mass spectrometer with an 
HP-1 column, and high resolution mass spectrometry was done on a Micromass VB-QTOF 
tandem mass spectrometer. IR spectrums were taken on FT/IR-410/C031560585 JASCO and 
Nexus 670 FT-IR E.S.P under neat conditions unless and otherwise stated. Melting points 
were taken on a Uni-melt capillary melting point apparatus and Digimelt MPA160 and 
recorded to a maximum of 260 °C. For products described as waxy solid, melting points 
could not be obtained. 
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Methyl 2-(2-nitro-1H-imidazol-1-yl)acetate (16a) 
N
N
OCH3
O
NO2
 
(16a) 
Potassium carbonate (1.8 g, 13.0 mmol) and tetrabutylammonium iodide (0.070 g, 0.19 
mmol) were added to a stirring solution of 2-nitroimidazole (1.0 g, 8.84 mmol) in 10 mL of 
dry acetonitrile. The reaction mixture was stirred at room temperature for 30 min and 
bromomethyl acetate (0.84 mL, 8.8 mmol) was added and heated to reflux for 45 min. After 
45 min, the reaction mixture was cooled to room temperature and filtered to remove 
inorganic salts and then washed with acetonitrile. All the organic washings were combined 
and concentrated in vacuo to get viscous liquid. Evaporation under high vacuum gave a crude 
solid, which was purified by column chromatography to obtain pure methyl 2-(2-nitro-1H-
imidazol-1-yl)acetate as light yellow solid (1.2 g, 6.5 mmol, 73%); mp: 95-96 °C; 1H NMR 
(400 MHz, CDCl3) δ 7.20 (d, J = 0.8 Hz, 1H), 7.08 (s, 1H), 5.13 (s, 2H), 3.80 (s, 3H); 13C 
NMR (100 MHz, CDCl3) δ 166.7, 144.8, 128.8, 126.7, 53.4, 51.0; HRMS (ESI, AccuTOF): 
[M+H]+ Calc’d for C6H8N3O4 m/z 186.0515. Found, m/z 186.0529. 
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Methyl 2-(4-nitro-1H-imidazol-1-yl)acetate (16b) 
N
N
OCH3
O
O2N
 
(16b) 
Potassium carbonate (1.8 g, 13.0 mmol) and tetrabutylammonium iodide (TBAI) (0.070 g, 
0.19 mmol) were added to a stirring solution of 4-nitroimidazole (1 g, 8.84 mmol) in 10 mL 
of dry acetonitrile. The mixture was stirred at room temperature for 30 min. After stirring 30 
min at room temperature, bromomethyl acetate (0.84 mL, 8.8 mmol) was added and heated to 
reflux for 45 min. After 45 min, the reaction mixture was cooled to room temperature and 
filtered to remove inorganic salts and washed with acetonitrile. All the organic washings 
were combined and concentrated in vacuo to obtain a crude solid, which was recrystallized 
from ethyl acetate to yield pure white crystals of methyl 2-(4-nitro-1H-imidazol-1-yl)acetate 
(1.3 g, 7.0 mmol, 79%);75 mp: 129-130 °C; 1H NMR (400 MHz, CDCl3) δ 7.83 (s, 1H), 7.47 
(s, 1H), 4.79 (s, 2H), 3.84 (s, 3H); 13C NMR (100 MHz, CDCl3) δ 166.5, 148.6, 136.9, 120.4, 
53.7, 48.9; HRMS (ESI, AccuTOF): [M + H]+ Calc’d for C6H8N3O4 m/z 186.0515. Found, 
m/z 186.0532. 
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N-(2-Hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide (17a) 
NN
H
N
O
O2N
OH
 
(17a) 
Methyl-2-(2-nitro-1H-imidazol-1-yl)acetate 16a (0.1 g,  0.54 mmol) was dissolved in 
methanol (2 mL), to this stirring solution 2-amino ethanol (0.31 g, 5.08 mmol) was added at 
room temperature and the resulting solution was stirred at room temperature overnight. The 
solvent was evaporated in vacuo to give a gummy viscous liquid, which was triturated with 
ethyl acetate to give a white solid which was filtered and dried under vacuum. This crude 
solid was purified by column chromatography (8% methanol in dichloromethane) to yield N-
(2-hydroxyethyl)-2-(2-nitro-1H-imidazol-1-yl)acetamide as a white powder (0.07 g, 0.33 
mmol, 60%);75 mp: 163.5-164.5 °C; 1H NMR (400 MHz, CD3OD) δ 7.45 (d, J = 0.9 Hz, 1H), 
7.18 (d, J = 1 Hz, 1H), 5.19 (s, 2H), 3.63 (t, J = 5.8 Hz, 2H), 3.36 (t, J = 5.8 Hz, 2H); 13C 
NMR (100 MHz, CD3OD) δ 168.3, 146.3, 129.3, 128.3, 61.4, 52.8, 43.1; HRMS (ESI-TOF): 
[M + H]+ Calc’d for C7H11N4O4 m/z 215.0780.  Found, m/z 215.0800.  
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N-(2-Hydroxyethyl)-2-(4-nitro-1H-imidazol-1-yl)acetamide (17b) 
NN
H
N
O
OH
O2N
 
(17b) 
2-(4-Nitro-1H-imidazol-1-yl)acetate 16b (0.3 g, 1.62mmol) was dissolved in methanol (5 
mL), to this stirring solution, 2-amino ethanol (0.31 g, 5.08 mmol) was added at room 
temperature and the solution was stirred at room temperature overnight. The resulting 
precipitate was filtered to give a white solid N-(2-hydroxyethyl)-2-(4-nitro-1H-imidazol-1-
yl)acetamide (0.31 g, 1.45 mmol, 90%); mp: 136-137 °C; 1H NMR (400 MHz, D2O) δ 8.20 
(d, J = 1.4 Hz, 1H), 7.77 (d, J = 1.4 Hz, 1H), 4.99 (s, 2H), 3.70-3.67 (m, 2H), 3.42-3.40 (m, 
2H); 13C NMR (100 MHz, D2O) δ 168.6, 146.8, 138.8, 122.8, 60.0, 50.1, 41.9; HRMS (ESI-
TOF): [M + H]+ Calc’d for C7H11N4O4 m/z 215.0780. Found, m/z 215.0824. 
 
2,3,3-Trimethyl-3H-indole-5-carboxylic acid (12) 
N
HOOC
 
(12) 
A 100 mL round-bottomed flask with was charged with 4-hydrazinobenzoic acid (4.5 g, 29.5 
mmol), 3-methyl 2-butanone (4.6 mL, 43 mmol), sodium acetate (4.86 g, 59 mmol), and 
glacial acetic acid (55 mL). The reaction mixture was stirred for 1 h under a nitrogen 
atmosphere and then heated at reflux overnight. The solvent was evaporated in vacuo and 80 
mL of 10% methanol in water was added.  The resulting precipitate was vacuum filtered to 
yield a tan powder (4.07 g, 20.0 mmol, 68%);75 mp: 205-208 °C decomposed; 1H NMR (400 
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MHz, CDCl3) δ 8.14 (d, J = 8.2 Hz, 1H), 8.05 (s, 1H), 7.64 (d, J = 8.1 Hz, 1H), 2.36 (s, 3H), 
1.36 (s, 6H); 13C NMR (100 MHz, CDCl3) δ 192.7, 171.4, 157.9, 145.9, 131.1, 126.9, 123.5, 
119.9, 54.2, 23.1, 15.8. GC-MS m/z (% relative intensity, ion): 203 [M]+, 188 [M-CO2]+, 
158 [M-2CH3];76 MS(ESI+): m/z 268 (50), 245 (45), 224 (90), 203.9 (100).77 
5-Carboxy-1-(δ-sulfobutyl)-2,3,3-trimethyl-3H-indolium (13) 
N
HOOC
SO3
 
(13) 
1,4-Butane sultone (2.95 mL, 28.8 mmol) was added to a stirring solution of 2,3,3-trimethyl-
3H-indole-5-carboxylic acid 12 (1.0 g, 4.9 mmol) in 20 mL of 1,2 - dichlorobenzene. The 
solution was heated at reflux overnight under a nitrogen atmosphere. The reaction mixture 
was cooled to room temperature and the resulting precipitate was filtered and washed with 
acetone and dried under vacuum to obtain 5-carboxy-1-(δ-sulfobutyl)-2,3,3-trimethyl-3H-
indolium as a pale pink powder (1.46 g, 4.3 mmol, 88%);75 mp: 230-232 °C decomposed; 1H 
NMR (400 MHz, CD3OD) δ 8.40 (d, J = 1.3 Hz, 1H), 8.34 (dd, J = 8.4, 1.6 Hz, 1H), 8.07 (d, 
J = 8.4 HZ, 1H), 4.61 (t, J = 7.8 Hz, 2H), 2.93 (t, J = 7.1 Hz, 2H), 2.24-2.16 (m, 2H), 2.02-
1.95 (m, 2H), 1.68 (s, 6H);78 13C NMR(100MHz, CD3OD) δ 201.1, 167.9, 145.6, 143.6, 
133.7, 132.3, 125.6, 116.8, 56.2, 51.0, 27.3, 23.2, 22.6; MS (ESI+): m/z 403.0 (30), 203.9 
(100), 296 (20), 268.1 (25).79 
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tert-Butyl piperazine-1-carboxylate (22) 
N
H
Boc
N
 
(22) 
A solution of di-tert-butyl dicarbonate (2.54 g, 11.6 mmol) in 30 mL of CH2Cl2 was added to 
a stirring solution of piperazine (2.0 g, 23.2 mmol) in 60 mL of CH2Cl2 at room temperature. 
The solution was stirred for 16 h at room temperature. The solvent was removed under 
reduced pressure and the residue was dissolved in water (50 mL). Aqueous solution was 
extracted with methylene chloride (4 × 60 mL). All the organic extracts were combined, 
dried over anhydrous magnesium sulfate and concentrated in vacuo to give a crude oil, which 
was purified by column chromatography to give tert-butyl piperazine-1-carboxylate as white 
solid (1.5 g, 8.05 mmol, 69%); mp: 46-47 °C; 1H NMR (400 MHz, CDCl3) δ 3.39-3.36 (m, 
2H), 2.81-2.78 (m, 2H), 1.57 (bs, 1H), 1.44 (s, 9H); 13CNMR (100 MHz, CDCl3) δ 154.3, 
79.8, 45.6, 44.5, 28.8; HRMS (ESI-TOF): [M + H]+ Calc’d for C9H19N2O2 m/z 187.1447. 
Found, m/z 187.0532. 
tert-Butyl-4-(2-bromoacetyl)piperazine-1-carboxylate (23) 
N
Boc
N
O Br
 
(23) 
Triethylamine (0.5 mL, 3.5 mmol) was added to a stirring solution of tert-butyl piperazine-1-
carboxylate 22 (0.60 g, 3.22 mmol) in 25 mL of dry dichloromethane at 0 °C. After stirring 
for 15 min at 0 °C, bromoacetyl bromide (0.3 mL, 3.5 mmol) was added dropwise. The 
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resulting reaction mixture was stirred at room temperature (c.a 48 h). The reaction progress 
was monitored by TLC. After the reaction completed, the mixture was concentrated in vacuo  
to give a crude solid which was purified by column chromatography (petroleum ether: ethyl 
acetate 15-20%) to give tert-butyl-4-(2-bromoacetyl)piperazine-1-carboxylate as a white 
solid (0.8 g, 2.6 mmol, 81%): mp: 95-97 °C; 1H NMR (400 MHz, CDCl3) δ 3.87 (d, J = 3.1 
Hz, 2H), 3.61-3.59 (m, 2H), 3.51-3.50 (m, 4H), 3.45-3.42 (m, 2H), 1.47 (s, 9H); 13C NMR 
(100 MHz, CDCl3) δ 165.7, 154.7, 80.7, 46.8, 42.2, 28.6, 25.8; HRMS (ESI-TOF): [M + H]+ 
Calc’d for C11H19BrN2O3 m/z 307.0657. Found, m/z 307.0652. 
tert-Butyl-4-(2-(2-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (24a) 
NN N
O
NBocO2N
 
(24a) 
Sodium hydride (0.025 g, 1.06 mmol) was added to a stirring solution of 2-nitroimidazole 
(0.1 g, 0.88 mmol) in 1 mL of dry DMF under a N2 atmosphere at 0 °C. The mixture was 
stirred at 0 °C temperature for 30 min, at that time, tert-butyl 4-(2-bromoacetyl) piperazine-1-
carboxylate (0.272 g, 0.88 mmol) was added slowly and the reaction mixture was stirred at 
room temperature overnight. The DMF was evaporated in vacuo and 5 mL of water was 
added to give a white precipitate, which was filtered and dried under vacuum to obtain tert-
butyl 4-(2-(2-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate as a white powder 
(0.28 g, 0.83 mmol, 93%); mp: 149-151 °C; 1H NMR (400 MHz, CDCl3) δ 7.21(d, J = 0.9 
Hz, 1H), 7.07 (s, 1H) 5.23 (bs, 2H), 3.62-3.59 (m, 4H), 3.52-3.47 (m, 4H), 1.48 (s, 9H); 13C 
NMR (100 MHz, CDCl3) δ 163.5, 154.5, 145.3, 128.4, 127.3, 80.8, 51.0, 45.1, 43.5, 42.5, 
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28.5; HRMS (ESI-TOF): [M + H]+ Calc’d for C14H22N5O5 m/z 340.1621. Found, m/z 
340.1608. 
tert-Butyl-4-(2-(4-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (24b) 
N
NO2N
N
O
NBoc
 
(24b) 
Sodium hydride (0.025 g, 1.06 mmol) was added to a stirring solution of 4-nitroimidazole 
(0.1 g, 0.88 mmol) in 1 mL of dry DMF under a N2 atmosphere at 0 °C. The mixture was 
stirred at 0 °C temperature for 30 min, at that time, tert-butyl 4-(2-bromoacetyl) piperazine-1-
carboxylate (0.272 g, 0.88 mmol) was added portionwise and the reaction mixture was stirred 
at room temperature overnight. The DMF was evaporated in vacuo and 5 mL of water was 
added to give a white precipitate,  which was filtered and dried under vacuum to obtain tert-
butyl 4-(2-(4-nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate as a white powder 
(0.25 g, 0.74 mmol, 83%);80 mp: 197-199 °C; 1H NMR (400 MHz, D2O) δ 7.58 (s, 1H), 7.41 
(s, 1H), 5.69 (s, 2H), 4.10-4.08 (m, 2H), 4.03-4.01 (m, 2H), 3.61-3.59 (m, 2H), 3.50-3.48 (m, 
2H); 1H NMR (400 MHz, CDCl3) δ 7.81 (s, 1H), 7.44 (d, J = 1.1 Hz, 1H), 4.87 (s, 2H), 3.65-
3.63 (m, 2H), 3.55-3.54 (m, 2H), 3.49-3.47 (m, 4H); 1.48 (s, 9H); 13C NMR (100 MHz, 
CDCl3) δ 163.4, 154.6, 148.2, 137.4, 121.5, 81.0, 49.0, 45.0, 42.5, 28.6; HRMS (ESI-TOF): 
[M + H]+ Calc’d for C14H22N5O5 m/z 340.1621. Found, m/z 340.1607. 
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2-(4-Nitro-1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone.trifluoroaceticacid salt (25b) 
N
N
N
O
N
H
TFA
O2N
 
(25b) 
Trifluoroacetic acid (1 mL) was added dropwise to a stirring solution of tert-butyl 4-(2-(4-
nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate 24b (0.28 g, 0.83 mmol) in 10 mL of 
dry chloroform. The solution was stirred at room temperature overnight. The reaction 
mixture was concentrated in vacuo to give a crude solid. The crude solid was triturated with 
ethyl acetate to give 2-(4-nitro-1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone TFA as a white 
solid, which was filtered and dried under vacuum (0.22 g, 0.62 mmol, 76%);81 mp: 228-
 229 °C; 1H NMR (300 MHz, D2O) δ 8.14 (d, J = 1.2 Hz, 1H), 7.72 (d, J = 1.2 Hz, 1H), 5.31 
(s, 2H), 3.90-3.87 (m, 4H), 3.44-3.41 (m, 2H), 3.37-3.33 (m, 2H); 13C NMR (75 MHz, D2O) 
δ 166.6, 163.4, 163.0, 162.5, 162.0, 146.7, 138.7, 123.5, 118.7, 49.0, 42.9, 42.9, 41.7, 39.2; 
HRMS (ESI-TOF): [M + H]+ Calc’d for C10H14F3N5O5 m/z 240.1096. Found, m/z 240.1100. 
2-(2-Nitro-1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone .TFA salt (25a) 
NN N
O
NH2O2N CF3COO
 
(25a) 
Trifluoroacetic acid (1 mL) was added dropwise to a stirring solution of tert-butyl 4-(2-(2-
nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate 24a (0.28 g, 0.83 mmol) in dry 
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chloroform (10 mL). The solution was stirred overnight at room temperature. The reaction 
mixture was concentrated to give a crude solid. The crude solid was triturated with ethyl 
acetate to give 2-(2-nitro-1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone TFA as a white 
solid, which was filtered and dried under vacuum (0.25 g, 0.71 mmol, 86%); mp: 120-
122 °C; 1H NMR (400 MHz, D2O) δ 7.58 (s, 1H), 7.40 (s, 1H), 5.68 (s, 2H), 4.08 (t, J = 4 
Hz, 2H), 4.03-4.00 (m, 2H), 3.59 (t, J = 4 Hz, 2H), 3.50-3.47 (m, 2H); 1H NMR (400 MHz, 
CD3OD) δ 7.45 (s, 1H), 7.22 (s, 1H), 5.54 (s, 2H), 3.89 (d, J = 13 Hz, 4H), 3.40-3.28 (m, 
4H); 13C NMR (100 MHz, CD3OD) δ 166.5, 162.4, 14.7, 129.3, 128.5, 52.0, 44.4, 42.9, 40.2; 
HRMS (ESI-TOF): [M-CF3COO+H]+ Calc’d for C9H14F3N5O3 m/z 240.1091. Found, m/z 
240.1149.  
tert-Butyl 4-(2-(1H-imidazol-1-yl)-2-oxoethyl)piperazine-1-carboxylate (29) 
N
N
N
N
Boc
O
 
(29) 
Method A:  
Sodium hydride (0.070 g, 2.93 mmol) was added to a stirring solution of imidazole (0.066 g, 
0.977 mmol) in 5 mL of dry THF under a N2 atmosphere at 0 °C. The mixture was stirred at 
the same temperature for 30 min. At that time, tert-butyl 4-(2-bromoacetyl) piperazine-1-
carboxylate (0.300 g, 0.977 mmol) was added portionwise and the reaction mixture was 
stirred at room temperature for 2 h. The reaction mixture was quenched with 15 mL of water 
and extracted with ethyl acetate (2 × 10 mL).  The organic extracts were combined, dried 
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over anhyd. MgSO4 and concentrated in vacuo to give a crude solid, which was purified by 
column chromatography to give tert-butyl 4-(2-(1H-imidazol-1-yl)-2-oxoethyl)piperazine-1-
carboxylate as a white solid (0.22 g, 0.75 mmol, 77%);80 mp: 147-149 °C; 1H NMR 
(400 MHz, CDCl3) δ 7.53 (s, 1H), 7.11 (s, 1H), 6.96 (s, 1H), 4.80 (s, 2H), 3.62 (bs, 2H), 3.48 
(bs, 6H), 1.47 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 165.0, 154.5, 138.1, 129.7, 120.2, 
80.8, 48.2, 45.1, 43.5, 42.2, 28.5; HRMS (ESI+TOF): [M+H]+ Calc’d for C14H23N4O3 m/z 
295.1770. Found, m/z 295.1751. 
Method B:  
Potassium carbonate (0.180 g, 1.30 mmol) was added to a stirring solution of imidazole 
(0.057 g, 0.847 mmol) in 3 mL of acetone, and then tert-butyl 4-(2-bromoacetyl) piperazine-
1-carboxylate (0.200 g, 0.651 mmol) was added portionwise. The reaction mixture was 
stirred at room temperature under a N2 gas for 4 h. The reaction mixture was filtered to 
separate the 1,3-disubstituted imidazolinium salt,  and the mother liquor was concentrated in 
vacuo to give a crude solid, which was purified by column chromatography to give tert-butyl 
4-(2-(1H-imidazol-1-yl)-2-oxoethyl)piperazine-1-carboxylate (0.18 g, 0.612 mmol, 73%); 
mp: 147-149 °C; 1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1H), 7.11 (s, 1H), 6.96 (s, 1H), 4.80 
(s, 2H), 3.62 (bs, 2H), 3.48 (bs, 6H), 1.47 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 165.0, 
154.5, 138.1, 129.7, 120.2, 80.8, 48.2, 45.1, 43.5, 42.2, 28.5; HRMS (ESI+TOF): [M+H]+ 
Calc’d for C14H23N4O3 m/z 295.1770. Found, m/z 295.1751. 
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tert-Butyl 4-(2-(1H-imidazol-1-yl)-2-oxoethyl)piperazine-1-carboxylate. TFA salt (30) 
N
N
N
N
H2CF3COO
O
 
(30) 
Trifluoroacetic acid (1 mL) was added dropwise to a stirring solution of tert-butyl 4-(2-(1H-
imidazol-1-yl)-2-oxoethyl)piperazine-1-carboxylate 29 (0.3 g, 1.02 mmol) in 10 mL of dry 
chloroform at room temperature. The solution was stirred at room temperature overnight. The 
reaction mixture was concentrated in vacuo to give a crude solid, which was triturated with 
ethyl acetate to give 2-(1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone.TFA as a white solid, 
which was filtered and dried under vacuum (0.28 g, 0.91 mmol, 89%); mp: 129-130 °C 
1H NMR (400 MHz, D2O) δ 8.76 (s, 1H), 7.53 (s, 1H), 7.46 (s, 1H), 5.43 (s, 2 H), 3.90-3.87 
(m, 4H), 3.44-3.41 (m, 2H), 3.36-3.34 (m, 2H); 13C NMR (100 MHz, D2O) δ 166.0, 163.4, 
163.0, 136.5, 123.6, 119.8, 118.0, 115.1, 50.1, 42.9, 41.8, 39.3; HRMS(ESI+TOF): [M-
CF3COO-+H] Calc’d for C9H15N4O m/z 195.1246. Found, m/z 195.1231. 
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Monosodium(II)mono(4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(2-nitro-1H-
imidazol-1-yl)acetyl)piperazine-1-carbonyl)-1-(4-sulfonatobutyl)-3H-indolium-2-
l)hepta-2,4,6-trienylidene)-3,3-dimethyl-5-(4-(2-(2-nitro-1H-imidazol-1-
yl)acetyl)piperazine-1-carbonyl)indolin-1-yl)butane-1-sulfonate) (26a) 
N
O3S
N
SO3Na
O
N
O
N
N
O
N
N
O
N
N
N
O2N
NO2
 
(26a) 
To a stirring solution of ICG bis-carboxylic acid 9 (0.2 g, 0.26 mmol) in dry DMF (2 mL) at 
0 °C was added pyBop (0.30 g, 0.57 mmol), HOBt (0.08 g, 0.57 mmol), DIPEA (220 µL, 
0.57 mmol) respectively. The mixture was stirred at 0 °C for 15 min. The 2-nitroimidazole 
piperazine fragment (25a) (0.204 g, 0.57 mmol) was added and stirred at room temperature 
for 48 h. The DMF was removed by air drying and the resulting crude reaction mixture was 
washed with acetonitrile (2×5 mL) and ethyl acetate (2×5 mL) to remove the soluble 
impurities. The crude solid was purified by C18 reverse phase column chromatography to 
yield 26a as a green solid (0.065 g, 0.055mmol, 20%); mp: decomposed to black residue > 
250 °C; 1H NMR (400 MHz, D2O) δ 7.84 (t, J = 12 Hz, 2H), 7.57 (bs, 2H), 7.44 (bs, 5H), 
7.35-7.33 (bs, 2H), 7.26 (m, 2H), 6.56 (t, J = 12.4 Hz, 2H), 6.29 (d, J = 13.2 Hz, 2H), 5.57-
5.49 (m, 4H), 4.15 (bs, 4H), 3.85-3.51 (m, 16H), 2.96 (t, J = 7.3 Hz, 4H), 1.98-1.96 (m, 4H), 
1.90-1.87 (m, 4H), 1.60 (bs, 12H); 13C NMR;82 HRMS (ESI-TOF): [M + 2H-Na]+ Calc’d for 
m/z C55H67N12O14S2 1183.4341. Found, m/z 1183.4399. 
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Monosodium(II)mono(4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(4-nitro-1H-
imidazol-1-yl)acetyl)piperazine-1-carbonyl)-1-(4-sulfonatobutyl)-3H-indolium-2-
l)hepta-2,4,6-trienylidene)-3,3-dimethyl-5-(4-(2-(4-nitro-1H-imidazol-1-
yl)acetyl)piperazine-1-carbonyl)indolin-1-yl)butane-1-sulfonate) (26b) 
N
O3S
N
SO3Na
O
N
O
N
N
O
N
N
O
N
N
NNO2
O2N
 
(26b) 
To a stirring solution of ICG bis-carboxylic acid 9 (0.09 g, 0.12 mmol) in dry DMF (2.5 mL) 
at 0 °C was added pyBop (0.135 g, 0.26 mmol), HOBt (0.035 g, 0.26 mmol), DIPEA (5 µL, 
0.29 mmol) respectively. The mixture was stirred at 0 °C and stirred for 15 min. The 4-
nitroimidazole piperazine fragment (0.107 g, 0.26 mmol) was added and stirred at room 
temperature for 48 h. The DMF was removed by air drying and the resulting crude reaction 
mixture was washed with acetonitrile (2×5 mL) and ethyl acetate (2×5 mL) to remove 
soluble impurities. The crude mixture was purified by C18 reverse phase column 
chromatography to yield 26b as a green solid (0.036 g,  0.030 mmol, 25%); mp: decomposed 
to a black residue > 250 °C; 1H NMR (400 MHz, DMSO-d6) δ 8.26 (s, 2H), 7.92 (t, J = 12 
Hz, 2H), 7.81 (s, 2H), 7.75 (s, 2H), 7.69 (s, 2H), 7.52-7.48 (m, 4H), 6.65-6.59 (m, 2H), 6.51 
(d, J = 8 Hz, 2H), 5.21 (bs, 4H), 4.11 (m, 4H), 3.58 (m, 16H), 1.80-1.71(m, 8H), 1.68 (s, 
12H); HRMS (ESI-TOF): [M-Na+H]+ Calc’d for C55H65N12O14S2 m/z 1181.4190. Found, 
m/z 1181.4174. 
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N-(2-Hydroxyethyl)-2-(4-nitro-1H-imidazol-1-yl)acetamido-ICG (10b) 
N
O3S
N
SO3Na
O
O
HN
O
N
N
NH
O
N
N
O
O
NO2
O2N
 
(10b) 
To a stirring solution of ICG bis carboxylic acid (0.2 g, 0.26 mmol) in dry DMF (2 mL) at 
0 °C was added pyBop (0.30 g, 0.57 mmol), HOBt (0.078 g, 0.57 mmol), DIPEA (260 µL, 
1.57 mmol) respectively. The mixture was stirred at 0 °C for 15 mn. The 4-nitroimidazole 
ethanolamine fragment (0.124 g, 0.57 mmol) was added and stirred at room temperature for 
48 h. The DMF was removed by air drying and the resulting crude reaction mixture was 
washed with acetonitrile (2×5 mL) and ethyl acetate (2×5 mL) to remove soluble impurities. 
The crude mixture was purified by C18 reverse phase column chromatography to yield 10b 
as a green solid (0.060 g, 0.052 mmols, 20%); mp: decomposed to black residue > 250 °C; 
1H NMR (400 MHz, DMSO-d6) δ 8.60-8.57 (m, 2H), 8.31 (s, 2H), 8.12 (s, 2H), 8.05 (d, J = 
16 Hz, 2H), 8.00-7.94 (m, 2H), 7.80 (s, 2H), 7.54 (d, J = 8 Hz, 2H), 6.68 (t, J = 12 Hz, 2H), 
6.56 (d, J = 12 Hz, 2H), 4.88 (s, 4H), 4.33-4.30 (m, 4H), 4.14 (bs, 4H), 3.54-3.52 (m, 4H), 
1.80-1.79 (m, 4H), 1.73 (t, J = 8 Hz, 4H), 1.67 (s, 12H); HRMS (ESI-TOF): [M+H]+ Calc’d 
for C51H60NaN10O16S2 m/z 1155.3528. Found, m/z 1155.3490. 
  
 Part I Experimental 
84 
 
N-(2-Hydroxyethyl)-2-(1H-imidazol-1-yl)acetamido-ICG (10a) 
N
O3S
N
SO3Na
O
O
HN
O
N
N
NH
O
N
N
O
O
O2N
NO2
 
(10a) 
To a stirring solution of ICG bis carboxylic acid 9 (0.2 g, 0.26 mmol) in dry DMF (2 mL) at 
0 °C was added pyBop (0.30 g, 0.57 mmol), HOBt (0.078 g, 0.57 mmol), DIPEA (260 µL, 
1.57 mmol) respectively. The mixture was stirred at 0 °C for 15 min. The 2-nitroimidazole 
ethanolamine fragment (0.124 g, 0.57 mmol) was added and stirred at room temperature for 
48 h. The DMF was by air drying and the resulting crude reaction mixture was washed with 
acetonitrile (2×5 mL) and ethyl acetate (2×5 mL) to remove soluble impurities. The crude 
mixture was purified by C18 reverse phase column chromatography to yield 10a as a green 
solid (0.105 g, 0.0091mmols, 35%); mp; decomposed to black residue > 250 °C; 1H NMR 
(400 MHz, DMSO-d6) δ 8.64-8.61 (m, 2H), 8.12 (s, 2H), 8.05 (d, J = 8 Hz, 2H), 8.00-7.88 
(m, 3H), 7.63 (s, 2H), 7.54 (d, J = 8 Hz, 2H), 7.20 (s, 2H), 6.67 (t, J = 12 Hz, 2H), 6.56 (d, J 
= 8 Hz, 2H), 5.14 (s, 4H), 4.29-4.28 (m, 4H), 4.14 (bs, 4H), 3.53-3.52 (m, 4H), 1.80-1.72 (m, 
8H), 1.67 (bs, 12H); 13C NMR (DMSO-d6) δ 166.5, 165.8, 146.7, 145.4, 141.6, 131.2, 129.3, 
127.9, 125.8, 123.7, 111.5, 64.0, 52.1, 51.2, 48.9, 44.2, 38.5, 27.6, 26.5, 22.9; HRMS (ESI-
TOF): [M+2H]+ Calc’d for C51H61N10O16S2 m/z 1133.3708. Found, m/z 1133.3765. 
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Monosodium(II)mono(4-((Z)-2-((2E,4E,6E)-7-(3,3-dimethyl-5-(4-(2-(1H-imidazol-1-
yl)acetyl)piperazine-1-carbonyl)-1-(4-sulfonatobutyl)-3H-indolium-2-l)hepta-2,4,6-
trienylidene)-3,3-dimethyl-5-(4-(2-(1H-imidazol-1-yl)acetyl)piperazine-1-
carbonyl)indolin-1-yl)butane-1-sulfonate) (31) 
N
O3S
N
SO3Na
O
N
O
N
N
O
N
N
O
N
N
N
 
(31) 
To a stirring solution of ICG bis carboxylic acid 9 (0.3 g, 0.39 mmol) in dry DMF (3 mL) at 
0 °C was added pyBop (0.45 g, 0.86 mmol), HOBt (0.117 g, 0.86 mmol), DIPEA (200 µL, 
1.18 mmol) respectively. The mixture was stirred at 0 °C for 15 min. The imidazole 
piperazine fragment (0.266 g, 0.86 mmol) was added and stirred at room temperature for 
48 h. The DMF was evaporated and the resulting solid was purified by C18 reverse phase 
column chromatography to yield 31 as a green solid (0.065 g, 0.0058 mmol, 15%); mp: 
decomposed to black residue >250 °C; 1H NMR (400 MHz, DMSO-d6) δ 7.92 (t, J = 12 Hz, 
2H), 7.69 (s, 2H), 7.51 (d, J = 16 Hz, 6H), 7.06 (s, 2H), 7.0-6.95 (m, 1H), 6.87 (s, 2H), 6.62 
(t, J = 12 Hz, 2H), 6.50 (d, J = 12 Hz, 2H), 5.06 (s, 4H), 4.10 (bs, 4H), 3.57 (bs, 16H), 1.77 
(m, 8H), 1.67 (s, 12H); HRMS (ESI-TOF): [M-Na]- Calc’d for C55H67N10O10S2 m/z 
1091.4483. Found, m/z 1091.4456. 
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N-((E)-(2-Chloro-3-((E)-(phenylimino)methyl)cyclohex-2-enylidene)methyl)aniline (63) 
Cl
N
H
N
HCl
 
(63) 
Phosphorus oxychloride (22 mL, 0.12 mol) was added dropwise to dimethylformamide 
(26 mL, 0.17 mol) at 0 ºC, and the resulting solution was stirred for 30 min. Cyclohexanone 
(11 mL, 0.053 mol), was added and the reaction mixture was heated at reflux for 1 h. The 
solution was cooled to ambient temperature, 36 mL of aniline/ethanol (1:1 (v/v)) mixture was 
added dropwise and the solution stirred for 30 min. The reaction mixture was poured into 220 
mL of ice cold water/concentrated HCl (10:1) and cooled for 2 h in an ice bath. Subsequent 
filtration gave a solid that was washed with cold water, diethyl ether and then acetone to give 
63 as a brick red solid (15.3 g, 42.7 mmol, 40%);71 mp: 190- 193 °C; 1H NMR (400 MHz, 
DMSO-d6) δ 11.35 (s, 2H), 8.29 (s, 2H), 7.44-7.42 (m, 4H), 7.25-7.18 (m, 6H), 7.05-7.02 
(m, 2H), 2.57-2.54 (m, 4H), 1.50-1.46 (m, 2H); 13C NMR (100 MHz, CD3OD) δ 173.7, 
168.6, 151.0, 146.0, 145.1, 141.5, 131.2, 128.8, 123.5, 110.9, 102.6, 50.5, 49.3, 44.2, 27.3, 
27.1, 26.2, 26.1, 22.4, 20.9. 
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N-((E)-(2-Chloro-3-((E)-(phenylimino)methyl)cyclopent-2-enylidene)methyl)aniline 
hydrochloride (64) 
Cl
N
H
N
HCl
 
(64) 
A stirred solution of N, N-dimethylformamide (13.5 g, 99.9 mmol) in chloroform (13 mL) 
was treated with phosphorous oxychloride (14 mL, 153 mmol) at 10 °C and stirred at 
ambient temperature for 1 h. Cyclopentanone (3.36 g, 39.9 mmol) was added and the solution 
was stirred at 50 °C for 4 h, cooled to ambient temperature and potassium carbonate (10 g, 
72.5 mmol) was added, followed by aniline (8.4 g, 90.2 mmol), concentrated HCl (7.5 mL) 
and water (50 mL) in that order. Subsequent stirring at ambient temperature for 1 h was 
followed by addition of CH2Cl2, A solid precipitated, which was filtered and washed with 
acetone (5×10 mL) and water (5×20 mL) to obtain 64 as a brick red colored powder (10 g, 
29.0 mmol, 73%); mp: 195-198 °C;83 1H NMR (400 MHz, DMSO-d6) δ 11.40 (bs, 2H), 8.30 
(s, 2H), 7.62-7.60 (m, 4H), 7.46 (t, J = 8 Hz, 4H), 7.27-7.24 (m, 2H), 3.02 (s, 4H); 13C NMR 
(100 MHz, DMSO-d6) δ 142.8, 140.5, 139.6, 139.3, 138.1, 130.2, 129.7, 129.5, 126.0, 122.9, 
118.5, 116.3, 114.9, 110.6, 26.1. 
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N-((E)-(2-Methyl-3-((E)-(phenylimino)methyl)cyclohex-2-enylidene)methyl)aniline (61)  
N
H
N
HCl
 
(61) 
A stirred solution of N-formyl-N-methylaniline (2.11 g, 15.6 mmol) in chloroform (2 mL) 
at -5 °C was treated with phosphorous oxychloride (1.5 mL, 15.6 mmol), dropwise, and 
stirred for 1 h at 10 °C. Methylcyclohexene (0.6 mL, 5.2 mmol) was added dropwise and the 
solution stirred at 45 °C for 20 h.  The reaction mixture was poured into a beaker containing 
vigorously stirred water (20 mL). Solid potassium carbonate (2 g, 14.5 mmol) was added 
carefully. A solution of aniline hydrochloride salt (1.52 g, 11.7 mmol) in water (3 mL) was 
added and the mixture stirred at ambient temperature for 30 min. At this time, potassium 
carbonate (2 g, 14.5 mmol) was added portionwise and the resulting solution cooled to give a 
precipitate that was filtered, washed several times with cold water and stirred vigorously with 
acetone (2×3 mL) filtered and dried in vacuo to afford 61 (0.68 g, 2.0 mmol, 39%);84 mp: 
207-210 °C; 1H NMR (400 MHz, CD3OD) δ 8.51 (s, 2H), 7.53-7.32 (m, 8H), 7.31-7.29 (m, 
2H), 2.64-2.61(m, 7H), 2.02-1.96 (m, 2H); 13C NMR (100 MHz, DMSO-d6) δ 165.9, 147.7, 
139.8, 129.6, 129.5, 129.3, 125.6, 118.8, 117.5, 115.1, 29.1, 23.5, 19.8, 14.3. 
  
 Part I Experimental 
89 
 
N-[5-Anilino-3-phenyl-2,4-(propane-1',3'-diyl)-2,4-pentadien-1-ylidene]anilinium 
Chloride (62) 
N
H
N
HCl
 
(62) 
A stirred solution of N-formyl-N-methylaniline (1.28 g, 9.5 mmol) in chloroform (2 mL) at -
 5 °C was treated with phosphorous oxychloride (0.9 mL, 9.5 mmol), dropwise, and stirred 
for 1 h at 10 °C. Phenylcyclohexene (0.5 g, 3.2 mmol) was added dropwise and then stirred 
at 45 °C for 20 h. The reaction mixture was poured into a beaker of vigorous stirred water 
(20 mL), and potassium carbonate (2 g, 14.5 mmol) was carefully added.  A solution of 
aniline hydrochloride salt (0.92 g, 7.11 mmol) in water (3 mL) was added and the mixture 
stirred at ambient temperature for 30 min. After then potassium carbonate (2 g, 14.5 mmol) 
was added portionwise. The mixture was cooled and the resulting precipitate was filtered, 
washed several times with cold water, stirred vigorously with acetone (2×10 mL), filtered 
and dried in vacuo to afford 62 as a dark red powder (0.85 g, 2.12 mmol, 67%);84 mp: 246-
250 °C; 1H NMR (400 MHz, DMSO-d6) δ 11.00 (s, 2H), 7.57-7.53 (m, 3H), 7.41-7.39 
(m, 2H), 7.36-7.32 (m, 4H), 7.24 (bs, 2H), 7.14 (t, J = 7.4 Hz, 2H), 7.06 (d, J = 7.9 Hz, 4H); 
13C (100 MHz, DMSO-d6) δ 157.8, 150.5, 142.0, 139.8, 136.2, 135.3, 134.7, 130.6, 130.2, 
129.8, 129.5, 128.3, 128.0, 125.8, 121.2, 118.7, 118.2, 114.6, 113.6, 23.9,23.3, 21.9, 20.5, 
19.8. 
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N-((1E,3E)-3-(Phenylimino)prop-1-enyl)benzenamine hydrochloride (70) 
N
HN
HCl
 
(70) 
A solution of distilled water (70 mL), HCl (5 mL) and aniline (3.7 mL, 0.04 mol) was added 
dropwise to a solution of propanedial bis(dimethyl acetal) (5.25 mL, 0.03 mol) and HCl 
(4.25 mL) in distilled water (90 mL) at 50 °C. The resulting solution was stirred at 50 °C for 
30 min. The reaction mixture was cooled, and the resulting precipitate was isolated by 
vacuum filtration and dried in vacuo to give 70 as an orange solid (6.35 g, 24.5 mmol, 
82%);85 mp: charring at 150 °C; 1H NMR (400 MHz, CDCl3) δ 8.75 (dd, J = 11.6, 6.1  Hz, 
2H), 7.46-7.39 (m, 9H), 7.24 (t, J = 7.1 Hz, 2H), 6.29 (t, J = 11.6 Hz, 1H); 13C NMR (100 
MHz, DMSO-d6) δ 159.6, 139.8, 131.1, 131.0, 127.6, 118.8, 118.7, 99.5, 99.4. 
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Sodium-2-((E)-2-((E)-3-((Z)-2-(5-carboxy-3,3-dimethyl-3-(4-sulfonatobutyl)lndolin-2-
ylidene)ethylidene)-2-chlorocyclopent-1-enyl)vinyl)-3,3-dimethylindole-1-sulfonate-5-
carboxylic acid (68) 
N
O3S
HOOC
Cl N
SO3Na
COOH
 
(68) 
A vigorously stirred solution of 3-(5-carboxy-2,3,3-trimethyl-3H-indolium-1-yl)propane-1-
sulfonate (0.197 g, 0.58 mmol) and 64 (0.1 g, 2.9 mmol) in acetic anhydride (1.5 mL) and 
acetic acid (1 mL) was treated with sodium acetate (0.084 g, 1.02 mmol) and heated at reflux 
(120 °C) for 45 min.  The reaction mixture was cooled to ambient temperature and anhydrous 
diethyl ether (10 mL) was added.  The resulting filtrate was isolated by vacuum filtration to 
give a crude solid that was recrystallized (methanol: water) to give 68 as a green solid 
(0.06 g, 0.07 mmol, 25%); mp: charring at 145-150 °C; 1H NMR (400 MHz, CD3OD) δ 
8.13-8.11 (m, 4H), 8.00 (d, J = 14.2 Hz, 2H), 7.43 (d, J = 8.2 Hz, 2H), 6.28 (d, J = 14.2 Hz, 
2H), 4.26 (t, J = 7.3 Hz, 4H), 3.06 (bs, 4H), 2.92 (t, J = 7.3 Hz, 4H), 2.05-1.97(m, 8H), 1.77 
(s, 12H); 13C NMR (100 MHz, DMSO-d6) δ 167.8, 167.0, 153.9, 148.6, 145.9, 141.2, 138.4, 
137.3, 130.8, 123.4, 122.6, 103.9, 99.4, 53.8, 51.3, 51.1, 50.7, 48.8, 44.5, 28.2, 27.7, 27.4, 
26.1, 23.0, 22.7, 22.5, 20.1; HRMS (ESI-TOF): [M + H]+ Calc’d for C39H45ClN2O10S2 m/z 
801.2282. Found, m/z 801.2367. 
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Sodium-2-((E)-2-((E)-3-((Z)-2-(5-carboxy-3,3-dimethyl-3-(4-sulfonatobutyl)lndolin-2-
ylidene)ethylidene)-2-chlorocyclohex-1-enyl)vinyl)-3,3-dimethylindole-1-sulfonate-5-
carboxylic acid (67) 
N
O3S
HOOC
Cl N
SO3Na
COOH
 
(67) 
A vigorously stirred solution of 3-(5-carboxy-2,3,3-trimethyl-3H-indolium-1-yl)propane-1-
sulfonate (13, 0.1 g, 0.29 mmol) and 63 (0.05 g, 0.14 mmol) in acetic anhydride (1 mL) and 
acetic acid (0.5 mL) was treated with sodium acetate (0.039 g, 0.47 mmol) and heated at 
reflux (120 °C) for 45 min.  The reaction mixture was cooled to ambient temperature and 
anhydrous diethyl ether (5 mL) was added.  The resulting precipitate was isolated by vacuum 
filtration to give a crude solid that was recrystallized (methanol: water) to give 67 as a green 
solid ( 0.055 g, 0.07 mmol, 47%); mp: charring at 130-140 °C; 1H NMR (400 MHz, CD3OD) 
δ 8.51 (d, J = 13.9 Hz, 2H), 8.15-8.11 (m, 4H), 7.46 (d, J = 8.7 Hz, 2H), 6.46 (d, J = 14.2 Hz, 
2H), 4.28-4.25 (m, 4H), 2.95-2.90 (m, 4H), 2.81-2.77 (m, 4H), 2.05-1.99 (m, 10H), 1.80 (s, 
12H); 13C NMR (100 MHz, CD3OD) δ 174.9, 169.8, 152.1, 147.2, 146.3, 142.7, 132.4, 
130.0, 124.7, 112.1, 103.7, 45.3, 28.5, 28.3, 27.4, 27.2, 23.6, 22.1; HRMS (ESI-TOF): 
[M+H]+ Calc’d for C40H48N2O10S m/z  815.2439. Found, m/z 815.2451. 
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Sodium-2-((E)-2-((E)-3-((Z)-2-(5-carboxy-3,3-dimethyl-3-(4-sulfonatobutyl)lndolin-2-
ylidene)ethylidene)-2-methylcyclohex-1-enyl)vinyl)-3,3-dimethylindole-1-sulfonate-5-
carboxylic acid (65) 
N
O3S
HOOC
Me N
SO3Na
COOH
 
(65) 
A vigorously stirred solution of 3-(5-carboxy-2,3,3-trimethyl-3H-indolium-1-yl)propane-1-
sulfonate (13, 0.107 g, 0.32 mmol) and 61 (0.05 g, 0.15 mmol) in acetic anhydride (1 mL) 
and acetic acid (0.5 mL) was treated with sodium acetate (0.041 g, 0.5 mmol) and heated at 
reflux (120 °C) for 45 min.  The reaction mixture was cooled to ambient temperature and 
anhydrous diethyl ether (5 mL) was added.  The resulting precipitate was isolated by vacuum 
filtration to give a crude solid that was recrystallized (methanol: water) to give 65 as a green 
solid (0.030 g, 0.04 mmol, 25%); mp: charring at 255-260 °C; 1H NMR (400 MHz, CD3OD) 
δ 8.23 (d, J = 13.6  Hz, 2H), 8.11 (d, J = 1.4 Hz, 1H), 8.09 (s, 2H), 7.37 (d, J = 8.4 Hz, 2H), 
6.37 (d, J = 13.8 Hz, 2H), 4.24-4.20 (m, 4H), 2.94-2.90 (m, 4H), 2.68-2.66 (m, 4H), 2.51 (s, 
3H), 2.03-1.93 (m, 10H), 1.79 (s, 12H); 13C NMR (100 MHz, CD3OD) δ 173.4, 158.4, 146.8, 
142.3, 134.1, 124.6, 111.4, 102.6, 52.0, 45.2, 28.7, 27.4, 26.6, 23.8, 15.4; HRMS (ESI-TOF): 
[M+H]+ Calc’d for C41H51N2O10S2 m/z 795.2985. Found, m/z 795.2964. 
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Sodium-2-((E)-2-((E)-3-((Z)-2-(5-carboxy-3,3-dimethyl-3-(4-sulfonatobutyl)lndolin-2-
ylidene)ethylidene)-2-phenylcyclohex-1-enyl)vinyl)-3,3-dimethylindole-1-sulfonate-5-
carboxylic acid (66) 
N
O3S
HOOC
N
SO3Na
COOH
 
(66) 
A vigorously stirred solution of 3-(5-carboxy-2,3,3-trimethyl-3H-indolium-1-yl)propane-1-
sulfonate (13, 0.36 g, 1.06 mmol) and 62 (0.2 g, 0.5 mmol) in acetic anhydride (1.5 mL) and 
acetic acid (1 mL) was treated with sodium acetate (0.139 g, 1.7 mmol) and heated at reflux 
(120 °C) for 45 min.  The reaction mixture was cooled to ambient temperature and anhydrous 
diethyl ether (15 mL) was added.  The resulting precipitate was isolated by vacuum filtration 
to give a crude solid that was recrystallized (methanol:water) to give 66 as a green solid 
(0.025 g, 0.03 mmol, 57%); mp: charring at 255-260 °C; 1H NMR (400 MHz, CD3OD) δ 
8.08 (d, J = 8.6 Hz, 2H), 7.94 (s, 2H), 7.68-7.64 (m, 3H), 7.39-7.35 (m, 4H), 7.30 (d, J = 6.6 
Hz, 2H), 6.36 (d, J = 13.9 Hz, 2H), 4.18 (bs, 4H), 2.93-2.90 (m, 4H), 2.80 (bs, 4H), 2.10 (bs, 
2H), 1.96 (bs, 8H), 1.25 (s, 12H); 13C NMR (100 MHz, CD3OD) δ 175.6, 169.2, 156.8, 
147.4, 142.8, 132.3, 128.7, 128.6, 124.6, 112.0, 106.0, 51.7, 50.4, 45.1, 27.9,27.2, 23.5; 
HRMS (ESI-TOF): [M+H]+ Calc’d for C46H53N2O10S2 m/z  857.3142. Found, m/z 857.3097. 
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Sodium 4-[2-[(1E,3E,5Z)-7-[1,1-dimethyl-3-(4-sulfonatobutyl)indol-2-ylidene]penta-1,3-
dienyl]-1,1-dimethylindol-3-ium-3-yl]butane-1-sulfonate (71) 
N
O3S
HOOC
N
SO3Na
COOH
 
(71) 
A vigorously stirred solution of 3-(5-carboxy-2,3,3-trimethyl-3H-indolium-1-yl)propane-1-
sulfonate (13, 0.14 g, 0.41 mmol) and 70 (0.05 g, 0.19 mmol) in acetic anhydride (1 mL) and 
acetic acid (0.5 mL) was treated with sodium acetate (0.054 g, 0.66 mmol) and heated at 
reflux (120 °C) for 45 min.  The reaction mixture was cooled to ambient temperature and 
anhydrous diethyl ether (5 mL) was added.  The resulting precipitate was isolated by vacuum 
filtration to give a crude solid that was recrystallized (methanol: water) to give 71 as a blue 
solid (0.09 g, 0.12 mmol, 63%); mp: decomposition at 287 °C; 1H NMR (400 MHz, CD3OD) 
δ 12.92 (bs, 2H), 8.43 (t, J = 13 Hz, 2H), 8.17 (s, 2H), 8.00 (d, J = 8.4 Hz, 2H), 7.53 (d, J = 
8.4 Hz, 2H), 6.71 (t, J = 12.4 Hz, 1H), 6.50 (d, J = 13.7 Hz, 2H), 4.15 (bs, 4H), 1.18-1.76 (m, 
8H), 1.73 (s, 12H); 13C NMR (100 MHz, CD3OD) δ 175.7, 169.2, 156.8, 147.4, 142.8, 132.3, 
128.7,128.6, 124.6, 112.0, 106.0, 51.7, 50.4, 45.1, 27.9, 27.2, 23.5; HRMS (TOF): [M+H]+ 
Calc’d for C35H43N2O10S2 m/z 715.2359. Found, m/z 715.2321. 
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4-Trimethylsilyloxy-2-methoxycyclohex-3-enecarbaldehyde (37) 
OMe
CHO
TMSO
 
(37) 
A mixture of trans-l-methoxy-3-trimethylsilyloxy-1,3-butadiene (0.5 g, 29 mmol) and 
acrylaldehyde (0.325 g, 5.8 mmol) in dry dichloromethane (10 mL) was heated to reflux at 
50 °C under a nitrogen atmosphere for overnight. The reaction mixture was concentrated in 
vacuo to give a crude oil, which was purified by column chromatography to obtain 4-
trimethylsilyloxy-2-methoxycyclohex-3-enecarbaldehyde as a clear oil (0.25 g, 1.09 mmol, 
38%); 1H NMR (400 MHz, CDCl3) δ 9.79 (s, 1H), 5.19 (d, J = 8 Hz, 1H), 4.28 (t, J = 4 Hz, 
1H), 3.33 (s, 3H), 2.45-2.41 (m, 1H), 2.18-2.08 (m, 2H), 2.05-1.97 (m, 1H), 1.95-1.88 (m, 
1H); 13C NMR (100 MHz, CDCl3) δ 203.4, 156.3, 102.1, 73.4, 56.0, 50.6, 29.1, 18.2, 0.4. 
Methyl-2-methoxy-4-trimethylsilyloxycyclohex-3-ene-1-carboxylate (44) 
OMe
COOMe
TMSO
 
(44) 
To a stirred solution of trans-1-methoxy-3-trimethylsilyloxybutadiene 16 (0.2 g, 1.16 mmol) 
in benzene (10 mL) was added methyl acrylate (0.21 mL, 24.0 mmol). The reaction mixture 
was heated at reflux for 48 h. The solution was concentrated to give 44 as an oil consisting of 
45:55 mixture of cis and trans isomers, which was used in the next step without further 
purification (0.28 g, 1.08 mmol, 94%); cis-isomer: 1H NMR (400 MHz, CDCl3) δ 4.98 (d, J 
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= 5.3, 1H), 4.10 (t, J = 4 Hz, 1H), 3.69 (s, 3H), 3.28 (s, 3H), 2.59 (dt, J = 12.2, 3.6, 1H), 
1.96-1.83 (m, 4H); 13C NMR (100 MHz, CDCl3) δ 173.1, 155.5, 101.5, 73.6, 55.9, 51.3, 44.5, 
29.4, 19.0, 0.3; tras-isomer: 1H NMR (400 MHz, CDCl3) δ 4.24 (bs, 1H), 5.13 (d, J = 4 Hz, 
1H), 3.70 (s, 3H), 3.31 (s, 3H), 1.96-1.83 (m, 5H), 0.20 (s, 9H); 13C NMR(100 MHz, CDCl3) 
δ 0.2, 22.7, 28.4, 44.2, 51.6, 55.4, 76.6, 102.9, 153.3, 174.2.86,87 
Methyl-4-oxocyclohex-1-enecarboxylate (51) 
COOMe
O
 
(51) 
A solution of methyl-2-methoxy-4-trimethylsilyloxycyclohex-3-ene-1-carboxylate, 44 (0.27 
g, 1.05 mmol) in toluene (5 mL) was cooled to 0 °C, yetterbium triflate (0.013 g, 2 mol%) 
was added and stirred for 45 min. The reaction mixture was evaporated in vacuo to give 
methyl-4-oxocyclohex-1-enecarboxylate as a crude oil which was purified by column 
chromatography (0.08 g, 0.52 mmol, 50%). Analytical characterization of the enone has been 
previously reported by Jung et al.88 1H NMR (300 MHz, CDCl3) δ 7.01 (m, 1H), 378 (s, 3H), 
3.04 (m, 2H), 2.81-2.76 (m, 2H), 2.56 (t, J = 8 Hz, 2H).  
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4-hydroxycyclohexa-1,3-dienecarbaldehyde (40) 
CHO
OH
 
(40) 
A solution of 0.1N HCl in tetrahydrofuran (1 mL) was added to a stirring solution of 37 in 
dichloromethane (0.1 g, 0.44 mmol) and the resulting solution was stirred overnight at room 
temperature. The solvent was removed in vacuo to get a crude oil. In an attempt to purify the 
crude, the desired product rearranged to a 4-hydroxycyclohexa-1,3-dienecarbaldehyde; 1H 
NMR (400 MHz, CDCl3) δ 9.42 (s, 1H), 6.89 (d, J = 4 Hz, 1H), 5.28 (d, J = 4 Hz, 1H), 2.57 
(t, J = 8 Hz, 2H), 2.42 (t, J = 8 Hz, 2H). 
(4Z)-4-((Phenyl lamino)methylene)cyclohex-2-enone (41) 
H
NO
 
(41) 
Yetterbium triflate (0.006 g, 2 mol%) was added to a stirring solution of 37 (0.1 g, 0.44 
mmol) in toluene (2 mL) at 0 °C and stirred at room temperature for 40 min. The reaction 
progress was monitored by TLC. After stirring at room temperature for 40 min, aniline 
(0.15 g, 1.61 mmol) was added to the same reaction pot and the resulting solution was stirred 
for overnight. Toluene was removed in vacuo to give the crude, which was purified by 
column chromatography to obtain (4Z)-4-((phenyllamino)methylene)cyclohex-2-enone 
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(0.026 g, 0.13 mmol, 29%); 1H NMR (400 MHz, CDCl3) δ 7.31 (s, 2H), 7.10-6.98 (m, 4H), 
6.98 (s, 1H), 5.70 (d, J = 4 Hz, 1H), 2.73 (bs, 2H), 2.55 (bs, 2H); 13C NMR (100 MHz, 
CDCl3) δ 199.2, 150.0, 141.3, 133.5, 129.9, 122.1, 119.3, 115.1, 109.4, 36.0, 21.8. 
Methyl 4-(4-nitrophenylamino)cyclohexa-1,3-dienecarboxylate (53) 
HN
COOMe
NO2
 
(53) 
A mixture of trans-l-methoxy-3-trimethylsilyloxy-1,3-butadiene (0.2 g, 1.16 mmol) and 
methyl acrylate (0.2 g, 2.32 mmol) in benzene (10 mL) was heated to reflux under a nitrogen 
atmosphere for 48 h. The reaction mixture was cooled to 0 °C, diisobutyl aluminium hydride 
(0.31g, 2.2 mmol) was added and the resulting solution was slowly warmed to room 
temperature and stirred for 2 h. The reaction progress was monitored by TLC. After the 
complete consumption of the Diels-Alder adduct, yetterbium triflate was added to the same 
reaction pot and stirred at room temperature for 2 h. The reaction progress was monitored by 
TLC. After the starting material consumption, 4-nitroaniline (0.07 g, 0.51 mmol) was added 
and the resulting solution was stirred at room temperature for overnight. The reaction mixture 
was concentrated in vacuo to give a crude, which was purified by column chromatography to 
obtain methyl 4-(4-nitrophenylamino)cyclohexa-1,3-dienecarboxylate (0.11 g, 0.40 mmol, 
35%); 1H NMR (300 MHz, CDCl3) δ 8.21 (d, J = 3 Hz, 2H), 7.20-7.15 (m, 3H), 5.93 (bs, 
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1H), 5.86 (d, J = 9 Hz, 1H), 3.79 (s, 3H), 2.68 (t, J = 9 Hz, 2H), 2.49 (t, J = 9 Hz, 2H); 13C 
NMR (75 MHz, CDCl3) δ 167.3, 153.4, 139, 131.8, 129.0, 121.6, 118.1, 69.8, 47.0, 
41.5.C17H24NO5S m/z 354.1375. Found, m/z 354.1375. 
Methyl 2-(1H-pyrrol-1-yl)acetate (75) 
N OMe
O
 
(75) 
Glycine methyl ester hydrochloride (3.0 g, 21.5 mmol) and sodium acetate (2.9 g, 12 mmol) 
were dissolved in water (15 mL). Acetic acid (30 mL) was then added. The solution was 
heated to reflux and 2,5-dimethoxytetrahydrofuran (2.9 mL, 22 mmol) was added. The 
mixture was heated at reflux for 4 hours before being allowed to cool to room temperature. 
The dark brown solution was diluted with water (120 mL), neutralised with solid NaHCO3 
(25 g) and extracted with CH2Cl2 (3×80 mL). The organic layers were dried (MgSO4), 
filtered, concentrated in vacuo to give a dark brown liquid. The material was purified by 
flash chromatography to give light brown oil (2.19 g, 15.7 mmol, 69%); 1HNMR (300 MHz, 
CDCl3) δ 6.63-6.62 (m, 2H), 6.17-6.16 (m, 2H), 4.62 (s, 2H), 3.72 (s, 3H); 13C NMR (75 
MHz, CDCl3) δ 169.7, 121.7, 108.9, 52.4; HRMS (ESI, AccuTOF): Calc’d for C7H10NO2 
[M+H]+ m/z 140.0712. Found, m/z 140.0693. 
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N-(2-Hydroxyethyl)-2-(1H-pyrrol-1-yl)acetamide (76) 
N N
H
O
OH
 
(76) 
Ethanolamine (12.6 g, 20.7 mmol) was added to a solution of Methyl 2-(1H-pyrrol-1-
yl)acetate (7.5 g, 54 mmol) in 50 mL of methanol and the resulting solution was stirred at 
room temperature for overnight. The reaction mixture was concentrated in vacuo to give a 
crude solid which was purified by column chromatography to give N-(2-Hydroxyethyl)-2-
(1H-pyrrol-1-yl)acetamide as an off white solid (6.5 g, 38.7 mmol, 72%); mp: 89-90 °C; 
1HNMR (300 MHz, CDCl3) δ 6.64 (d, J = 1.68 Hz, 2H), 6.22 (d, J = 1.68 Hz, 2H), 5.79 (bs, 
1H), 4.57 (bs, 2H), 3.61-3.58 (m, 2H), 3.35-3.30 (m, 2H), 2.52 (bs, 1H); 13C NMR (75 MHz, 
CDCl3) δ 170.1, 121.8, 110.1, 61.4, 52.9, 41.2; HRMS (ESI, accuTOF): [M+NH3]+ Calc’d 
for C7H12N2O2 m/z 156.0899. Found, m/z 156.0655. 
2-(4-nitro-1H-imidazol-1-yl)acetic acid (18) 
 
(18) 
A 50 mL round-bottomed flask with a magnetic stirbar was charged with methyl 2-(4-nitro-
1H-imidazol-1-yl)acetate 16b (1.0 g, 5.40 mmol), and 30 mL of water. The system was 
heated under reflux for 24 hours.  Then, the solution was cooled, and any remaining solid 
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was filtered off.  The water was removed in vacuo, and solid was placed in drying pistol with 
phosphorus pentoxide for 24 h, to give a white solid (0.88 g, 5.14 mmol, 97%); mp: 151-152 
°C; 1H NMR (400 MHz, DMSO-d6): δ 8.12 (d, J = 0.84 Hz, 1H), 7.59 (d, J = 1.12 Hz, 1H), 
4.74 (s, 2H); 13C NMR (100 MHz, CD3OD): δ 170.0, 148.4, 139.2, 122.8, 53.3; HRMS(ESI-
TOF): [M+H]+ Calc’d for C5H6N3O4: m/z 172.0358. Found, m/z 172.0369. 
5-Carboxylate-1-(δ-sulfobutyl)-2,3,3-trimethyl-3H-indolium (88) 
N
MeOOC
SO3
 
(88) 
A 50 mL round-bottomed flask with a magnetic stirbar was charged with the carboxylic acid 
indolium salt 13 (1.01 g, 2.97 mmol), and absolute methanol (15 mL). The mixture was 
stirred at room temperature under nitrogen as oxalyl chloride (1.0 mL, 11.9 mmol) was added 
dropwise. Then the mixture was stirred for 24 h. The mixture was reduced in vacuo to give a 
red paste. The crude product was stirred in ether until it became a suspension, about 24 h. 
The solid was filtered and washed with ether to yield a red powder (1.02 g, 2.89 mmol, 
97%); mp: decompose at 159 °C; 1H NMR (400 MHz, CD3OD): δ 8.34 (d, J = 1.1 Hz, 1H), 
8.28 (dd, J = 8.5, 1.5 Hz, 1H), 8.05 (d, J = 8.5 Hz, 1H), 4.57 (t, J = 7.8 Hz, 2H), 3.95 (s, 3H), 
2.89 (t, J = 7.1 Hz, 2H), 2.18-2.11 (m, 2H), 1.97-1.91 (s, 2H), 1.63 (s, 6H); 13C NMR (100 
MHz, CD3OD) δ 22.6, 23.3, 27.3, 53.1, 56.3, 116.9, 125.5, 132.1, 133.0, 143.7, 145.8, 166.9, 
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201.3. HRMS (ESI, accuTOF): [M+H]+ Calc’d for C17H24NO5S m/z 354.1375. Found: m/z 
354.1375. 
Bis-1-1′-(4-sulfobutyl)indoletricarbocyanine-5-carboxy-5′-carboxylate sodium salt (89) 
N
O3S
MeOOC
N
SO3Na
COOH
 
(89) 
A 100 mL round-bottomed flask with a magnetic stirrbar was charged with the carboxylic 
acid indolium salt 13 (0.50 g, 1.47 mmol) and N-[5-(Phenylamino)-2,4-
pentadienylidene]aniline monohydrochloride  (0.37 g, 1.49 mmol).  Then acetic anhydride 
(19 mL) and glacial acetic acid (12 mL) were added to flask. The mixture was stirred as 
sodium acetate (0.48 g, 5.84 mmol) was added. The solution was heated at reflux under a 
nitrogen atmosphere for 30 min.  Next, the methyl ester indolium salt 88 (0.54 g, 1.52 mmol) 
was added to the flask, and the mixture continued to reflux for an additional 45 minutes.  The 
mixture was cooled to room temperature, and then poured into 150 mL of hot anhydrous 
ether. The solution was cooled at 5 °C overnight, and then the precipitate was filtered and 
washed with ether. The collected solid was recrystallized in a 1:4 mixture of water and 
propanol.  The crystals were filtered and dried for two days under vacuum to yield a blue 
green powder (0.96 g, 1.24 mmol, 83%); mp: decomposed at 238-239 °C; 1H NMR (400 
MHz, DMSO-d6) δ 12.96 (bs, 1H), 8.08 (d, J = 7.34 Hz, 2H), 7.97 (d, J = 7.34 Hz, 2H), 7.84 
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(m, 2H), 7.52 (d, J = 9.05 Hz, 2H), 7.47 (s, 1H), 6.48 (m, 4H), 4.15-4.06 (m, 4H), 3.86 (s, 
3H), 1.73 (s, 8H), 1.63 (s, 12H); 13C NMR (100 MHz, DMSO-d6) δ 167.7, 166.6, 147.1, 
142.0, 131.3, 125.6, 124.0, 123.8, 52.8, 51.4, 49.4, 41.8, 27.7, 26.8, 23.2; HRMS (ESI-TOF): 
[M+Na]+ Calc’d for C38H45N2NaO10S2 m/z 755.2736. Found, m/z 777.2540. 
tert-Butyl 4-(2-(2-methyl-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate (79) 
N
N
N
N
Boc
O
 
(79) 
Sodium hydride (0.0235 g, 1.46 mmol) was added to a stirring solution of 2-methylimidazole 
(0.1 g, 1.22 mmol) in 1 mL of dry DMF under a N2 atmosphere at 0 °C. The mixture was 
stirred at 0 °C temperature for 30 min, at that time, tert-butyl 4-(2-bromoacetyl) piperazine-1-
carboxylate (0.374 g, 1.22 mmol) was added slowly and the reaction mixture was stirred at 
room temperature overnight. The DMF was evaporated in vacuo and the resulting crude 
reaction mixture was purified by column chromatography to give tert-butyl 4-(2-(2-methyl-
1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate as a colorless oil (0.263 g, 0.85 mmol, 
69%); mp: 147-149 °C; 1H NMR (400 MHz, CDCl3) δ 6.81 (s, 1H), 7.70 (s, 1H) 4.58 (s, 2H), 
3.50 (m, 2H), 3.35 (m, 6H), 2.20 (s,3H), 1.38 (s, 9H); 13C NMR (100 MHz, CDCl3) δ 164.9, 
154.3, 145.4, 127.1, 120.3, 80.5, 53.5, 47.2, 44.6, 43.3, 43.1, 41.9, 28.3, 12.9.80 
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2-(2-methyl-1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone.TFA salt (80) 
N
N
N
N
H2
O
CF3COO
 
(80) 
Trifluoroacetic acid (1 mL) was added dropwise to a stirring solution of tert-butyl 4-(2-(4-
nitro-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate  79 (0.26 g, 0.85 mmol) in 10 mL of 
dry chloroform. The solution was stirred at room temperature overnight. The reaction 
mixture was concentrated in vacuo to give a crude solid. The crude solid was triturated with 
ethyl acetate to give 2-(2-methyl-1H-imidazol-1-yl)-1-(piperazin-1-yl)ethanone TFA as a 
white solid, which was filtered and dried under vacuum (0.24 g, 0.75 mmol, 88%); mp:150-
152 °C; 1H NMR (300 MHz, DMSO-d6) δ 7.32-7.27 (m, 2H), 5.41 (s, 3H), 5.28 (s, 2H), 3.78  
(d, J = 4 Hz, 4H), 3.32-3.31 (m, 2H), 3.25-3.20 (m, 2H); 13C NMR (75 MHz,CD3OD) δ 
165.5, 162.5, 162.0, 161.5, 161.0, 147.7, 124.7, 119.4,118.9,115.6, 44.2, 43.0, 40.3, 10.7; 
HRMS(ESI-TOF): (submitted for HRMS) 
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1,3-bis-tert-Butyl-4-(2-(1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate bromide (28) 
NN
N NBoc
N
NBoc
Br
O
O
 
(28) 
tert-Butyl 4-(2-bromoacetyl)piperazine-1-carboxylate (0.9 g, 29.4 mmol) was added to a 
stirring solution of imidazole (0.2 g, 29.4 mmol) in dry DMF (2 mL) and the resulting 
solution was stirred overnight at room temperature. The solvent was evaporated in vacuo and 
the resulted solid was washed with water (5 mL) to remove inorganic salts and then the solid 
was filtered to obtain 1,3-bis-tert-butyl-4-(2-(1H-imidazol-1-yl)acetyl)piperazine-1-
carboxylate bromide (1.3 g, 2.16 mmol, 74%); mp: decomposed to black residue at >270 °C; 
1H NMR (400 MHz, CDCl3) δ 9.82 (s, 1H), 7.45 (s, 1H), 5.53 (bs, 4H), 3.61-3.58 (m, 4H), 
3.56-3.54 (m, 4H), 3.52-3.51 (m, 4H), 3.46-3.44 (m, 4H), 1.57 (bs, 2H), 1.45 (s, 18H); 13C 
NMR (100 MHz, CD3OD) δ 165.4, 156.2, 124.7, 81.8, 45.7, 44.1, 43.3, 28.6; 
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1,3-bis-tert-Butyl-4-(2-(2-methyl-1H-imidazol-1-yl)acetyl)piperazine-1-carboxylate 
bromide (92) 
NN
N NBoc
N
NBoc
Br
O
O
 
(92) 
Followed the same procedure as in the preparation of 28; 1H NMR (400 MHz, CDCl3) δ 7.62 
(s, 2H), 5.60 (bs, 4H), 3.64(m, 8H), 3.59-3.56 (m, 6H), 3.48-3.45 (m, 6H), 1.47 (s, 18H); 13C 
NMR (100 MHz, CD3OD) δ 170.4, 165.1, 156.2, 149.3, 123.5, 81.7, 45.8, 43.2, 28.6, 22.4; 
mp: 241-242 °C 
(Z)-N-(2-Phenylisoindolin-1-ylidene)benzenamine (59) 
N
N
 
(59) 
Aniline was added to a solution of phthalaldehyde (1 g, 7.45 mmol) in ethanol (20 mL) and 
the resulting solution was heated to reflux overnight. The solid precipitated in the reaction 
mixture was filtered and dried under vacuum to obtain (Z)-N-(2-phenylisoindolin-1-
ylidene)benzenamine (1.9 g, 6.68 mmol, 90%); mp: 140-142 °C; 1H NMR (400 MHz, 
CDCl3) δ 8.01 (d, J = 7 Hz, 2H), 7.47-7.33 (m, 5H), 7.11-7.00 (m, 5H),6.68 (d, J = 7.4 Hz, 
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2H), 4.96 (s, 2H); 13C NMR (100 MHz, CDCl3) δ 153.4, 150.7, 141.6, 140.4, 131.5, 130.4, 
129.2, 129.0, 127.3, 126.5, 123.1, 122.8, 122.3, 121.3, 119.9, 53.0. 
2-(4-nitro-1H-imidazol-1-yl)acetic acid.piperazine salt (20) 
N
N
O
O
O2N
N
H
H2
N
 
(20) 
A 50 mL round bottom flask was charged with 2-(4-nitro-1H-imidazol-1-yl)acetic acid 18 
(0.050 g, 29.2 mmol) and piperazine (0.025 g, 29.2 mmol) in CH2Cl2 (3 mL). EDC 
hydrochloride salt (0.056 g, 29.2 mmol) was added at 0 °C and the resulting solution was 
slowly warmed up to room temperature and stirred for overnight. The resulted solid was 
filtered and dried under vacuum (0.06 g, 86%); 1H NMR (300 MHz, CD3OD) δ 7.78 (d, J = 
0.75 Hz, 1H), 7.25 (s, 1H), 3.31-3.29 (s, 10H); 13C NMR (75 MHz, CD3OD) δ 170.0, 148.9, 
146.3, 131.4, 49.8, 53.3. 
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INFLUENCE OF DISTAL METHYL GROUP ON BASE INDUCED 
ISOMERIZATION OF TERMINAL ALKYNES 
 Kinetic studies of terminal alkynes 
179 
 
Chapter 6.  
KINETICS OF BASE INDUCED ISOMERIZATION OF TERMINAL ALKYNES 
6.1 Periodontal disease 
Though we clean our mouth every day, it is true that our mouths are always filled with 
bacterial microflora, which consists of aerobic and anaerobic bacteria. These bacteria form 
colonies in biofilms on the surface of the tooth. These bacteria combines with other particles 
and mucus to form a sticky material called “plaque”. Prolonged accumulation of plaque 
becomes “tartar” which is hard to remove by brushing the teeth. The longer it stays, the more 
damage it can bring to the teeth. Because of the bacterial inflammation gums become red, 
swollen and bleeds easily. This type of gum disease is called “Gingivitis”, and it is a mild 
form of gum disease and easily cured. When gingivitis left untreated, it advances to 
“Periodontitis”. In this later stage, the body reacts to the bacterial growth along the gum line 
and the gums pull away from teeth and develop spaces which are called “pockets” (Figure 
6.1). When these pockets become severely infected by the bacterial inflammation, the 
alveolar bones and the supporting tissues are broken down. The damage caused by gingivitis 
can be reversed with proper treatment whereas complete restoration of supporting tissues in 
periodontitis is impossible. 
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Figure 6.1. Healthy and Periodontitis diseased teeth (source: WebMD)89 
6.2 Porphyromonas gingivalis and aliphatic alkynes 
The anaerobic, Gram-negative organism, Porphyromonas gingivalis, is thought to be a 
major periodontal pathogen associated with inflammatory periodontal disease in adults. Lipid 
extracts of P. gingivalis are known to potentiate prostaglandin secretion from gingival 
fibroblasts when co-treated with interleukin-1b, and more recent work demonstrated that 
phosphorylated dihydroceramides, particularly phosphoglycerol dihydroceramides, are the 
primary biologically active lipid constituents.90-92 These phosphorylated dihydroceramides 
have unusual sphinganine base and fatty acid components. The work in Frank Nicholas lab 
and Smith lab has shown that the dihydroceramides have isobranched C17 and C19 aliphatic 
chains that comprise the long chain bases in an amide linkage to 3-OH isobranch C17 fatty 
acids 19. (Figure 6.2) 
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Figure 6.2. Retrosynthesis of phosphorylated dihydroceramides 
 In previous work, our lab synthesized the putative C17 and C19 long chain bases to 
prove their structure, and showed them to be isobranched, and that the isobranched aliphatic 
chains were critical for expression of biological activity.93 We initially prepared the 
appropriate dihydroshphingasine derivatives, both isobranched and straight-chain via 
synthesis of the long-chain terminal alkyne, followed by coupling to Garner’s aldehyde. 94,95 
Preparation of the straight-chain terminal alkyne was straightforward, but attempts to 
generate the corresponding isobranched alkyne proved to be difficult. We observed rapid 
isomerization of the terminal alkyne to the internal alkyne, leading to poor isolated yields of 
the isobranched alkyne. The base-induced isomerization of triple bonds is well known,96-101 
proceeding through the allene intermediate:102  In general, strong bases such as NaNH2 
convert internal alkynes to terminal alkynes because the equilibrium is shifted by formation 
of the acetylide ion. With weaker bases such as NaOH (which are not strong enough to 
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remove the acetylenic proton), the internal alkynes are favored because of their greater 
thermodynamic stability 
If the temperature of the reaction was raised to ambient temperature or above, the base-
induced isomerization was rapid, which was not a surprise. This isomerization was easily 
controlled by temperature control for the straight-chain alkynes, but not for the isobranched 
alkynes. We observed that long-chain alkynes with a terminal isobranch, distal to the 
terminal alkyne appeared to isomerize faster than the analogous straight chain alkyne. This 
isomerization was an interesting reaction and we turned our attention to probe the reason for 
the reactivity of the isobranched alkyne. We therefore examined the kinetics of the base 
induced isomerization to gain information that would help us to understand this unusual, and 
to our knowledge unprecedented observation. 
6.3 Synthesis of C17 iso-branch and C18 straight chain external alkynes  
To determine the kinetics of base induced isomerization for both the straight-chain 
terminal alkyne 2 and the iso-branched terminal alkyne 6, we prepared each by routes that are 
somewhat different from conditions used in our initial work. Synthesis of the straight-chain 
alkyne 2 was straightforward and coupling of lithium acetylide with commercially available 
1-bromohexadecane 1 in dry DMSO gave 1-octadecyne 2 in 73% yield. We prepared 13-
methyl-1-bromotetradecan-1-ol 4 using methodology reported by Singh103-105 and by Mori, 
106
 in which the cuprate-mediated coupling reaction of the Grignard reagent prepared in situ 
from 1-bromo-2-methylpropane 3 and commercially available 11-bromoundecan-1-ol. 
Conversion of 4-methylpentan-1-ol 4 to the corresponding bromide 5 was achieved with 
NBS and PPh3 in chloroform. The 1-bromo-4-methylpentane 5 was reacted with lithium 
acetylide ethylene diamine complex to give 15-methyl-1-hexadecyne 6. 
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Scheme 6-1. Synthesis of 1-Octadecyne (C-18 straight chain external alkyne, 2) 
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Scheme 6-2. Synthesis of 15-methyl-1-hexyne (C17 iso-branched external alkyne, 6)  
We heated both 2 and 6 with potassium tert-butoxide in DMSO, and observed 
formation of the internal alkyne, 7 and 8 respectively. In both cases, equilibrium was reached 
favoring 7 and 8, with small amounts of 2 and 6. We determined the equilibrium constants to 
be K(6) = 32.3 and K(2 ) = 46.6, indicating that 2 goes further towards completion relative to 
the reaction of 6. 
10
6
9
8
10 10
DMSO
DMSO
2 7
KOt-Bu,
KOt-Bu,
 
Figure 6.3. Isomerization of 2 and 6 
The base induced isomerization of terminal alkynes to internal alkynes is well known. 
It was reported that the reaction of 1-hexyne with potassium tert-butoxide, in DMSO at 25-40 
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°C, isomerized to 2-hexyne in 4 hours.107 Interestingly, if the reaction was heated to 72 °C for 
92 hours, the product was 2,4-hexadiene. Smadja observed a similar isomerization to 2-
hexyne with potassium tert-butoxide in tert-butanol at 143 °C in four hours.108 In that work, a 
mechanism was proposed for an equilibrium reaction involving the terminal alkyne, the 
internal alkyne and an allene intermediate. Indeed, isomerization of internal alkynes to 
terminal alkynes via a similar allene-mediated mechanism is well known.109 Therefore, our 
observations that isomerization of 2 and 6 in DMSO to reach an equilibrium mixture is 
entirely consistent with previously reported results. A tentative alkyne:allene:alkyne 
equilibrium can be assembled, adapted from similar work for 1,4-diynes discussed by 
Mathai, et. al.110  This diagram indicated that deprotonation of terminal alkyne 8 to give 9 is 
in equilibrium with α-deprotonation of 8 to give 10 (Figure 6.5). Due to the relatively high 
pKa of the α-proton in particular, we believe that tert-butoxide reacts with DMSO to generate 
small concentrations of potassium methylsulfinylmethylide (dimsyl potassium, 14) as the 
relevant base, accounting for the pseudo first order behavior. Once formed, anion 10 removes 
a proton, presumably from DMSO, to give allene 11. 1,3-Proton transfers have been reported 
that involve allenes111-113 and base  mediated isomerization of terminal alkynes that involve 
allenes.114 Subsequent deprotonation to give 12 is followed by formation of the final product 
12. This mechanistic diagram115,116 represents the equilibrium mixture that favors the 
thermodynamically more stable internal alkyne 12. It is noted that internal alkynes can be 
isomerized to terminal alkynes with Li diamines. Interestingly, we observed a larger 
equilibrium constant for the straight chain alkyne 2 when compared to the isobranched 
alkyne 6.  
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Figure 6.5 Proposed mechanism of terminal alkyne isomerization 
 Kinetics for isomerization of both 2 and 6 were determined in DMSO at 55 °C and 
also at 75 °C, temperatures at which reasonable data could be collected. Samples were 
prepared at 0.042 M alkyne in DMSO. Potassium tert-butoxide was added and aliquots were 
removed at the indicated time intervals shown in the following tables and quenched with 
water, the products extracted with hexane, and proton NMR data were collected at 300 MHz 
and 400 MHz. 
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Table 6-1. Kinetic data for octadec-1-yne 2 at 52-55 °C 
Time 
(min) 
Weight of 
octadec-1-yne 2 
(mg) 
Weight of 
octadec-2-
yne 7 (mg) 
Mmoles of 
octadec-1-
yne 2 
Mmoles of 
octadec-2-
yne 7 
Rel % of  
octadec-1-yne 
2 52-55 oC 
 
0 
 
5 
 
0 
 
0.02 
 
0 
 
100 
10 4.93 0.07 0.01972 0.00028 98.6 
20 4.875 0.125 0.0195 0.0005 97.5 
30 4.745 0.255 0.01898 0.00102 94.9 
40 4.635 0.365 0.01854 0.00146 92.7 
50 4.53 0.47 0.01812 0.00188 90.6 
60 4.425 0.575 0.0177 0.0023 88.5 
70 4.335 0.665 0.01734 0.00266 86.7 
80 4.24 0.76 0.01696 0.00304 84.8 
90 4.06 0.94 0.01624 0.00376 81.2 
100 4.035 0.965 0.01614 0.00386 80.7 
110 3.94 1.06 0.01576 0.00424 78.8 
120 3.835 1.165 0.01534 0.00466 76.7 
130 3.75 1.25 0.015 0.005 75 
190 3.075 1.925 0.0123 0.0077 61.5 
250 2.685 2.315 0.01074 0.00926 53.7 
260 2.685 2.315 0.01074 0.00926 53.7 
310 2.475 2.525 0.0099 0.0101 49.5 
370 2.285 2.715 0.00914 0.01086 45.7 
430 2.045 2.955 0.00818 0.01182 40.9 
600 1.53 3.47 0.00612 0.01388 30.6 
660 1.25 3.75 0.005 0.015 25 
720 1.035 3.965 0.00414 0.01586 20.7 
780 0.91 4.09 0.00364 0.01636 18.2 
 Kinetic studies of terminal alkynes 
187 
 
840 0.86 4.14 0.00344 0.01656 17.2 
900 0.745 4.255 0.00298 0.01702 14.9 
960 0.665 4.335 0.00266 0.01734 13.3 
1020 0.56 4.44 0.00224 0.01776 11.2 
1080 0.535 4.465 0.00214 0.01786 10.7 
1140 0.485 4.515 0.00194 0.01806 9.7 
1200 0.44 4.56 0.00176 0.01824 8.8 
1400 0.42 4.58 0.00168 0.01832 8.4 
1520 0.38 4.62 0.00152 0.01848 7.6 
1800 0.355 4.645 0.00142 0.01858 7.1 
1980 0.28 4.72 0.00112 0.01888 5.6 
2040 0.21 4.79 0.00084 0.01916 4.2 
3600 0.105 4.895 0.00042 0.01958 2.1 
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Table 6-2. Kinetic data for octadec-1-yne (2) at 72-75 °C 
Time 
(min) 
Weight of 
octadec-1-yne 
2 (mg) 
Weight of 
octadec-2-
yne 7 (mg) 
Mmoles of 
octadec-1-
yne 2 
Mmoles of 
octadec-2-
yne 7 
Rel % of  
octadec-1-yne 2 
73-75 oC 
 
0 
 
5 
 
0 
 
0.02 
 
0 
 
100 
10 4.337 0.663 0.017348 0.002652 86.74 
20 3.487 1.513 0.013948 0.006052 69.74 
30 2.7775 2.2225 0.01111 0.00889 55.55 
40 2.3495 2.6505 0.009398 0.010602 46.99 
50 1.852 3.148 0.007408 0.012592 37.04 
60 1.5475 3.4525 0.00619 0.01381 30.95 
70 1.294 3.706 0.005176 0.014824 25.88 
80 1.043 3.957 0.004172 0.015828 20.86 
90 0.912 4.088 0.003648 0.016352 18.24 
100 0.798 4.202 0.003192 0.016808 15.96 
110 0.674 4.326 0.002696 0.017304 13.48 
120 0.611 4.389 0.002444 0.017556 12.22 
130 0.568 4.432 0.002272 0.017728 11.36 
140 0.5055 4.4945 0.002022 0.017978 10.11 
150 0.4495 4.5505 0.001798 0.018202 8.99 
160 0.443 4.557 0.001772 0.018228 8.86 
170 0.4665 4.5335 0.001866 0.018134 9.33 
180 0.371 4.629 0.001484 0.018516 7.42 
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Table 6-3. Kinetic data for methylhexadec-1-yne 6 at 52-55 °C 
Time 
(min) 
Weight of 15-
methylhexade
c-1-yne 6 
(mg) 
Weight of 15-
methylhexade
c-2-yne 8 
(mg) 
Mmoles of 
15-
methylhexade
c-1-yne 6 
Mmoles of 15-
methylhexadec
-2-yne 8 
Rel % of  
methylhexade
c-1-yne 6 52-
55 oC 
 
0 
 
5 
 
0 
 
0.021186441 
 
0 
 
100 
10 3.9 1.1 0.016525424 0.004661017 78 
20 3.47 1.53 0.01470339 0.006483051 69.4 
30 3.215 1.785 0.013622881 0.007563559 64.3 
40 3.14 1.86 0.013305085 0.007881356 62.8 
50 2.99 2.01 0.012669492 0.008516949 59.8 
60 2.74 2.26 0.011610169 0.009576271 54.8 
70 2.59 2.41 0.010974576 0.010211864 51.8 
80 2.53 2.47 0.010720339 0.010466102 50.6 
90 2.26 2.74 0.009576271 0.011610169 45.2 
110 2.24 2.76 0.009491525 0.011694915 44.8 
120 1.975 3.025 0.008368644 0.012817797 39.5 
140 1.85 3.15 0.007838983 0.013347458 37 
200 1.38 3.62 0.005847458 0.015338983 27.6 
260 1.065 3.935 0.004512712 0.016673729 21.3 
380 0.66 4.34 0.00279661 0.018389831 13.2 
500 0.51 4.49 0.002161017 0.019025424 10.2 
600 0.26 4.74 0.001101695 0.020084746 5.2 
660 0.21 4.79 0.000889831 0.02029661 4.2 
720 0.15 4.85 0.000635593 0.020550847 3 
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Table 6-4. Kinetic data for methylhexadec-1-yne 6 at 72-75 °C 
Time 
(min) 
Weight of 15-
methylhexade
c-1-yne 6 
(mg) 
Weight of 15-
methylhexade
c-2-yne 8 
(mg) 
Mmoles of 
15-
methylhexade
c-1-yne 6 
Mmoles of 
15-
methylhexade
c-2-yne 8 
Rel % of  
methylhexade
c-1-yne 6 72-
75 oC 
 
0 
 
5 
 
0 
 
0.021186441 
 
0 
 
100 
10 3.4945 1.5055 0.014807203 0.006379237 69.89 
20 2.6665 2.3335 0.011298729 0.009887712 53.33 
30 1.693 3.307 0.007173729 0.014012712 33.86 
40 1.5505 3.4495 0.006569915 0.014616525 31.01 
50 1.3935 3.6065 0.005904661 0.01528178 27.87 
60 1.193 3.807 0.005055085 0.016131356 23.86 
70 0.9445 4.0555 0.004002119 0.017184322 18.89 
90 0.76 4.24 0.003220339 0.017966102 15.2 
100 0.6285 4.3715 0.002663136 0.018523305 12.57 
110 0.5415 4.4585 0.002294492 0.018891949 10.83 
120 0.4985 4.5015 0.002112288 0.019074153 9.97 
130 0.39 4.61 0.001652542 0.019533898 7.8 
140 0.375 4.625 0.001588983 0.019597458 7.5 
150 0.3725 4.6275 0.00157839 0.019608051 7.45 
160 0.3235 4.6765 0.001370763 0.019815678 6.47 
170 0.327 4.673 0.001385593 0.019800847 6.54 
180 0.3775 4.6225 0.001599576 0.019586864 7.55 
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(a) ln[alkyne] at 52-55 °C (b) ln[alkyne] at 72-75 °C 
Figure 6.6. Plot of ln [2] and ln [6] versus time (min) at 55 °C and 75 °C. 
 We initially assumed that the base induced isomerization reaction was a second order 
reaction between the alkyne and the tert-butoxide base, and therefore plotted 1/[alkyne] 
versus time (in minutes). However, plots of 1/[alkyne] did not show a straight line 
relationship.  As shown in Figure 6.6 plots of ln [alkyne] versus time gave straight line plots. 
We interpret these results to indicate that the isomerization follows pseudo first order 
kinetics. If this interpretation is correct, the tert-butoxide likely reacts with the DMSO 
sodium to produce dimsyl sodium, which would be the active base in the reaction and 
consistent with a pseudo first order process. We have screened a set of solvents which 
includes polar protic, and aprotic, to understand the role of solvent in the isomerization 
reaction. Alkyne isomerization was tried at 85 °C and 100 °C. Alkyne isomerization did not 
happen in any of the solvents, which supports the hypothesis of dimsyl ion 14 formation in 
the reaction (Table 6-5) 
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Table 6-5. Terminal alkyne isomerization in different sovents  
Alkyne Solvent Temperature Result 
 
2 
t-Butanol 85 °C No Isomerization 
Dimethoxy ethane 85 °C No Isomerization 
1,4-Dioxane 100 °C No Isomerization 
Sulfolane 85 °C No Isomerization 
 
6 
t-Butanol 85 °C No Isomerization 
Dimethoxy ethane 85 °C No Isomerization 
1,4-Dioxane 100 °C No Isomerization 
Sulfolane 85 °C No Isomerization 
 
 Based on Figure 6.6, it is clear that isomerization of the isobranched alkyne 6 is faster 
than that of the straight-chain alkyne 2. We calculated a pseudo-first order rate constant for 
reactions done at 55 °C using the slope of the plots in Figure 6.6(a) and obtained a value of -
7.38 x 10-3 mol-1 min-1 for the isobranched alkyne 6 and -2.23 x 10-3 mol-1 min-1 for the 
straight chain alkyne 2. Kinetic data for the same reactions done at 75 °C are shown in Figure 
6.6(b), and gave a rate of -2.27 x 10-2 mol-1 min-1 for 6 and -1.99 x 10-2 mol-1 min-1 for 2.  
Although 6 isomerizes about 3.25 times faster than 2. For both 6 and for 2, the isomerization 
does not go to completion, but rather reaches an equilibrium of about 95-97% internal + 3-
5% terminal alkyne.  
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Figure 6.7. Plot of ln [6] vs time (min) at 55 °C and 75 °C and ln [2] vs time (min) at 55 °C 
and 75 °C  
 Using the data at 55 °C and 75 °C, we calculated the activation energy for each 
alkyne isomerization reaction was calculated using the formula: 
 
Where k2 = rate of alkyne (2/6) at T2 , k1 = rate of alkyne (2/6) at T1, Ea = activation energy, 
R = 8.314 J K-1 mol-1, T1 = 55 °C = 328 K and T2 = 75 °C = 348 K.  As shown in Table 6-6, 
calculations showed that Ea for 2 = 3.19 × 10-3 J mol-1, and Ea for 6 = 2.09 × 10-3 J mol-1.  
This data suggests that isomerization of the isobranched alkyne is more difficult. 
 The faster rate of isomerization for 6 relative to 2 is clear, including the lower 
activation barrier for the reaction. The real question is why does a methyl group at the end of 
a long carbon chain have an influence of the rate of a reaction at the other end of the 
molecule? It is reasonable to assume that difference in rate are likely due to some 
intermolecular interaction that makes the isobranched alkyne more available for reaction, or 
an intramolecular interaction related to conformation. Bohn’s work with relatively short 
k2
k1
ln 1
T1
1
T2
–R
Ea
=
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chain alkynes raises a point that may be relevant to our work. Microwave spectroscopic 
analysis of several alkynes presented evidence or the presence of an intramolecular CH/Π-
interaction that stabilized gauche conformations relative to more open conformations.117 It is, 
therefore, possible that long-chain alkynes exist in folded or coiled conformations in 
relatively large percentages. While speculative, such coiling could bring the distal end of the 
alkyne into closer proximity to the alkyne unit that is involved in the base-induced 
isomerization. Simple energy calculations for such coiled conformations of 2 and of 6 
indicated that coiled 6 was about 2.4 kJ higher in energy. If correct, the isobranch would tend 
to be “less coiled” than the straight chain alkyne, presumably making the propargylic carbon 
and possibly the terminal alkyne proton of the isobranched alkyne more available for reaction 
with base, leading to a faster rate of isomerization.(Figure 6.8) 
6 2
 
Figure 6.8 Spartan 3D images of coiled conformations of 6 and 2 
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Table 6-6. Rate data for 2 and 6 at 55 °C and 75 °C 
Alkyne 
Pseudo first order  
rate constant at 55 °C  
(Mol-1 min-1) 
Pseudo first order  
rate constant at 75 °C  
(Mol-1 min-1) 
Activation energy 
Ea (J Mol-1) 
2 -2.23 × 10-3 -18.49 × 10-3 3.19 × 10-3 
6 
-4.64 × 10-3 -18.75 × 10-3 2.09 × 10-3 
 This proposal is certainly highly speculative, but it is reasonable to assume that 
difference in rate are likely due to some intermolecular interaction that makes the 
isobranched alkyne more available for reaction, or an intramolecular interaction related to 
conformation. To the best of our knowledge, except for Bohn’s work, the literature does not 
provide precedent for either case. Therefore, we present our findings that the presence of a 
distal methyl group undergoes base-induced isomerization about 3 times faster than the 
straight chain analog, and offer a possible explanation based on a novel and speculative 
conformational effect. 
 To further validate this hypothesis, we synthesized heptadec-1-yne 18 and hexadec-1-
yne 16. The synthesis of each alkyne is straight forward. When the corresponding alkyl 
bromides 15, 17 treated with lithium acetylide EDA complex, terminal alkynes 16, 18 were 
obtained. To understand the effect of chain length on the isomerization, we studied the 
kinetics of 16 and 18. 
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Br
LiC CH.EDA
dry DMSO
r.t., overnight hexadec-1-yne
15 16
 
Scheme 6-3. Synthesis of hexadec-1-yne 16 
Br
heptadec-1-yne
LiC CH.EDA
dry DMSO
r.t., overnight
17 18
 
Scheme 6-4. Synthesis of heptadec-1-yne 18 
When we attempted the kinetic studies, we found an interesting observation, the time 
required for the experiments was much shorter although the trend of isomerization was 
maintained (the isobranch is faster than straight chain). We ran the experiments with fresh 
DMSO from a new bottle. To double check our previous results, we ran the kinetics 
experiments with the old DMSO and the results were repeated as before. We assumed that 
the old bottle was contaminated with water and calculated the water content in the DMSO 
using a Karl Fisher Coulometer.118 The water content in the old DMSO was found to be 
4.38%. We rationalized the results to be either water stabilizing the coiled conformations of 
alkynes or quenching of the dimisyl anion. We don’t know the answer yet, but it is clear that 
the isobranched alkyne isomerizes faster than the straight chain alkyne. This unexpected 
observation has opened up more questions. If our hypothesis is true, we want to explain how 
water effects the coiled conformations in solution?  To fully understand the effect of water, it 
is important to look at the energies of coiled conformation of alkynes in presence of water. 
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Molecular modeling studies that incorporate the hydrophobic interactions between the long 
aliphatic chains of alkynes and water may be useful. We are collaborating with Dr. Jose 
Gascon for the molecular modelling experiments on alkynes. After observing the water effect 
on the isomerization, we conducted the kinetic studies on hexadec-1-yne 16, heptadec-1-yne 
18, octadec-1-yne 2 and 15-methylhexadec-1-yne 6 with fresh DMSO and the data will be 
analyzed including the molecular modelling studies. 
heptadec-1-yne heptadec-2-yne
hexadec-2-yne
18 19
2016
DMSOKOt-Bu,
DMSOKOt-Bu,
 
Scheme 6-5. Isomerization of hexadec-1-yne 16, heptadec-1-yne 18 
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6.4 Experimental: 
All glassware was flame-dried under nitrogen, and all reactions were performed under 
a nitrogen atmosphere. All chemicals were purchased from the Aldrich Chemical Co., and 
used without further purification. The tetrahydrofuran was dried over sodium–benzophenone 
and distilled immediately prior to its use. The 1H NMR (400 MHz) and the 13C NMR 
(100.65 MHz) were recorded on a Brücker DRX-400 instrument, in CDCl3 unless otherwise 
noted, and all chemical shifts are reported relative to tetramethylsilane (TMS) as an internal 
standard. Infrared spectra were recorded on a JASCO FT/IR-410 instrument, and reported in 
cm–1. Mass spectra were recorded on a Hewlet-Packard 5970 GC/MS instrument. High 
resolution mass spectrometry of new compounds was performed on a Micromass VB-QTOF 
tandem mass spectrometer. 
All chemicals were used as received from Aldrich or Acros. All glassware was flame-
dried under vacuum, and all reactions in organic solvents were performed under a nitrogen 
atmosphere, unless otherwise noted. All solvents were dried according to standard 
procedures.  THF was distilled from sodium benzophenone ketyl, methylene chloride was 
distilled from calcium hydride, and dimethylformamide was vacuum distilled from calcium 
hydride. Thin-layer chromatography was done on Sorbent Technologies aluminum-backed 
TLC plates with fluorescent indicator and 0.2 mm silica gel layer thickness, and p-
anisaldehyde, Phosphomolybdic acid were used as developing agents. Column 
chromatography was done using 60 Å porosity, 32-63 µm silica gel. 1H and 13C NMR were 
collected on a Brüker Avance 300 (300.13 MHz 1H, 75.48 MHz 13C), Brüker DRX-400 
(400.144 MHZ 1H, 100.65 MHz 13C) or a Brüker Avance 500 (500.13 MHz 1H, 125.65 MHZ 
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13C). Chemical shifts are given in ppm downfield from TMS in the following format 
chemical shift, multiplicity (s=singlet, d=doublet, t=triplet, q=quartet, m=multiplet) coupling 
constant in Hz and Integration. Mass spectroscopy data was collected on a HP 5870B 
GC/MSD mass spectrometer with an HP-1 column, and high resolution mass spectrometry 
was done on a Micromass VB-QTOF tandem mass spectrometer. IR spectrums were taken on 
FT/IR-410/C031560585 JASCO and Nexus 670 FT-IR E.S.P under neat conditions unless 
and otherwise stated. Melting points were taken on a Uni-melt capillary melting point 
apparatus and Digimelt MPA160 and recorded to a maximum of 270 °C. For products 
described as waxy solid, melting points could not be obtained. 
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Octadec-1-yne (2) 
 
(2) 
Lithium acetylide (0.3 g, 3.2 mmol) was added to a stirring solution of 1-
bromohexadecane 1 (0.5 g, 1.64 mmol) in dry DMSO (3 mL) and the resulting solution was 
stirred overnight at room temperature. Reaction progress was monitored by TLC. After the 
reaction completed, the reaction mixture was quenched with 50 mL of H2O and extracted 
with diethyl ether (2×25 mL).  The organic extracts were washed with water (50 mL), brine 
and dried over anhydrous MgSO4 and concentrated in vacuo to give a crude solid, which was 
purified by column chromatography (100% hexane) to obtain octadec-1-yne as a clear oil 
which become white solid up on cooling in an ice bath (0.3 g, 1.20 mmol, 73%);119 mp: low 
melting solid (26-27 ºC); IR (neat) 3287, 2915, 2954, 2848, 2115, 1462, 682 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 2.18 (td, J = 7.1, 2.5 Hz, 2H), 1.93 (t, J = 2.5 Hz, 1H), 1.56-1.49 (m, 2 
H), 1.40-1.37 (m, 2 H), 1.26 (bs, 24 H), 0.86 (m, 3H); 13C NMR (75 MHz, CDCl3) δ 84.8, 
68.2, 32.2, 30.0, 29.9, 29.8, 29.6, 29.4, 29.0, 28.8, 22.9, 18.6, 14.3. 
Octadec-2-yne (7) 
 
(7) 
Mp: low melting solid (27-28 °C); IR (neat); 2954, 2912, 2871, 2847, 1470,716 cm-1; 
1H NMR (400 MHz, CDCl3) δ 2.11 (tq, J = 5.0, 2.4 Hz, 2H), 1.78 (t, J = 2.5 Hz, 3H), 1.50-
1.43 (m, 2H), 1.37-1.32 (m, 2H), 1.26 (bs, 24H), 0.88 (m, 3H); 13C NMR (100 MHz, CDCl3) 
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δ 79.6, 75.4, 32.1, 29.9, 29.7, 29.5, 29.4, 29.3, 29.1, 22.9, 18.9, 14.3, 3.6; HRMS (ESI-TOF): 
[M+H]+ Calc’d for C18 H34 m/z 251.2739.  Found, m/z 251.2714. 
13-Methyltetradecan-1-ol (4) 
OH
 
(4) 
Magnesium turnings (1.52 g, 62.7 mmol) were suspended in dry THF (25 mL) and 1-
bromo-2-methyl propane (5.7 mL, 52.5 mmol) was added with vigorous stirring under a 
nitrogen atmosphere at room temperature. After the reaction mixture started refluxing, 
another 25 mL of dry THF was added and the reaction mixture was stirred until it cooled to 
room temperature and turned light brown. In a separate flask LiCl (0.71 g, 16.7 mmol) and 
CuCl2 (1.09 g, 8.12 mmol) were dissolved in dry THF (15 mL) and stirred for 30 minutes at 
room temperature. The Grignard solution was cooled to -78 ºC.  A solution of 11-bromo-1-
undecanol in dry THF (7 mL) was added slowly via syringe, followed by a solution 
containing the Li2CuCl4 salt in THF and the resulting solution was warmed to room 
temperature and stirred overnight. The reaction mixture was quenched with saturated 
aqueous ammonium chloride (50 mL), washed with H2O (50 mL) and extracted with diethyl 
ether (3×50 mL). The organic extracts were combined and washed with saturated aqueous 
NaHCO3 (3×50 mL), brine, and dried over MgSO4. The solvent was removed in vacuo to 
give a crude oil which was further purified by flash column chromatography (9:1 petroleum 
ether: ethylacetate) to yield 13-methyltetradecanol as a white solid (1.44 g, 6.32 mmol, 
79%)120-122; mp: 30-31 ºC; 1H NMR (300 MHz, CDCl3) δ 3.64 (t, J = 6.6 Hz, 2H), 1.59-1.47 
(m, 4H), 1.26 (bs, 18H) 1.16-1.13 (m, 3 H), 0.86 (d, J = 6.6 Hz, 6H); 13C NMR (75 MHz, 
CDCl3) δ 63.3, 39.3, 33.1, 30.2, 29.9, 29.8, 29.7, 28.2, 27.6, 26.0, 22.9.  
Part II Experimental 
202 
 
1-Bromo-13-methyltetradecane (5) 
Br
 
(5) 
To a stirred solution of 13-methyltetradecanol 4 (1.44 g, 6.32 mmol) in dry 
dichloromethane (40 mL) was added triphenylphospine (2.38 g, 9.08 mmol).  The resulted 
solution was cooled to 0º C, and N-Bromosuccinimide (1.54 g, 8.65 mmol) was added in 
portionwise and the solution was warmed to room temperature stirred overnight at room 
temperature.  The solvent was evaporated in vacuo and the residue was stirred in hexane (50 
mL). The resulted slurry was filtered and the cake washed several times with hexane (5×5 
mL).  The filtrate was concentrated in vacuo to give an oil which was purified by flash 
column chromatography (100% petroleum ether) to obtain 1-bromo-13-methyltetradecane as 
a clear oil (1.48 g, 5.09 mmol, 81%); 1H NMR (300 MHz, CDCl3) δ 3.37 (td, J = 6.9, 2.0, 
Hz, 2H), 1.89-1.79 (m, 2H), 1.61-1.48 (m, 1H), 1.45-1.40 (m, 2H), 1.27 (bs, 16H), 1.17-1.15 
(m, 2H), 0.84 (dd, J = 6.7, 2.2 Hz, 6 H); 13C NMR (75 MHz, CDCl3) δ 39.3, 33.7, 33.1, 30.2, 
30.0, 29.9, 29.8, 29.7, 29.0, 28.5, 28.2, 27.7, 22.8, 14.3.  
15-Methylhexadec-1-yne (6) 
 
(6) 
Lithium acetylide EDA complex (0.190 g, 2.05 mmol) was added to the stirring 
solution of 1-bromo-13-methyltetradecane 5 (0.12 g, 0.41 mmol) in dry DMSO (3 mL) and 
the resulted solution was at room temperature for overnight. The reaction progress was 
monitored by TLC. The reaction mixture was quenched with H2O (30 mL) and extracted 
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with diethyl ether (3×10 mL). The organic extracts were washed with water (50 mL), brine 
(50 mL) and dried over anhydrous MgSO4. The solvent was removed in vacuo to give 15-
methylhexadec-1-yne as an oil, which was purified by column chromatography (straight 
hexane) to obtain a clear oil (0.075 g, 3.18 mmol, 77%); IR (KBr, CH2Cl2) 3315, 2960, 2925, 
2855, 2120, 1466, 1261, 1095, 803, 629 cm-1; 1H NMR (300 MHz, CDCl3) δ 2.17 (td, J = 
6.9, 2.5 Hz, 2H), 1.92 (t, J = 2.6 Hz, 1H), 1.54-1.47 (m, 3H), 1.38 (m, 2H), 1.26 (bs, 16 H), 
1.16 (m, 2H), 0.86 (d, J = 6.6 Hz, 6H); 13C NMR (75 MHz, CDCl3) δ 84.9, 68.2, 39.3, 30.2, 
30.0, 29.9, 29.8, 29.7, 29.4, 29.0, 28.7, 28.2, 27.7, 22.9, 18.6; HRMS (ESI-TOF): [M+H]+ 
Calc’d for C17H32 m/z 236.2504. Found, m/z 236.2524.123,124 
15-Methylhexadec-2-yne (8) 
 
(8) 
IR (neat); 2921, 2852, 1465, 1383, 1365,720, 698 cm-1;1H NMR (400 MHz, CDCl3) δ 
2.11 (tq, J = 5.0, 2.4 Hz, 2H), 1.77 (t, J = 2.5 Hz, 3H), 1.54-1.43 (m, 3H), 1.37-1.34 (m, 2H), 
1.26 (bs, 14H), 1.21-1.12 (m, 2H), 0.86 (d, J = 6.6 Hz, 6H); 13C NMR (100 MHz, CSCl3) δ 
79.6, 75.4, 39.3, 30.1, 29.9, 29.8, 29.7, 29.4, 29.3, 29.1, 28.2, 27.6, 22.8, 18.9, 3.6; HRMS 
(ESI-TOF): [M+H]+ Calc’d for C17H32 m/z 237.2582. Found, m/z 237.2582. 
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Heptadec-1-yne (16) 
 
(16) 
Lithium acetylide EDA complex (0.63 g, 6.86 mmol) was added to the stirring 
solution of 1-bromopentadecane 17 (1.0 g, 3.43 mmol) in dry DMSO (15 mL) and the 
resulted solution was at room temperature for overnight. The reaction progress was 
monitored by TLC. The reaction mixture was quenched with H2O (30 mL) and extracted 
with diethyl ether (3×10 mL). The organic extracts were washed with water (50 mL), brine 
(50 mL) and dried over anhydrous MgSO4. The solvent was removed in vacuo to give 15-
methylhexadec-1-yne (6) as an oil, which was purified by column chromatography (straight 
hexane) to obtain 15-methylhexadec-1-yne (0.78 g, 2.69 mmol, 78%); IR (neat); 3314, 2921, 
2852, 1675, 1654, 1594, 1485,1465, 1432, 1403, 1348, 1306, 1282, 1254, 1207, 
1177,1120,1062 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.18 (td, J = 7, 2.5 Hz, 2H), 1.93 (t, J = 
2.6 Hz, 1H), 1.56-1.49 (m, 2H), 1.40 (m, 2H), 1.26 (bs, 22 H), 0.90-0.86 (m, 3H); 13C NMR 
(400 MHz, CDCl3) δ 85.0,, 68.2, 32.1, 29.9, 29.8, 29.7, 29.6, 29.3, 29.0, 28.7, 22.9, 18.6, 
14.3; HRMS (ESI-TOF): [M+H]+ Calc’d for C17H32 m/z 237.2582. Found, m/z 237.2579. 
Heptadec-2-yne (7) 
 
(7) 
IR (neat); 2920, 2852, 1680, 1601, 1493, 1453, 1348, 1311,1264, 1026 cm-1; 1H NMR 
(400 MHz, CDCl3) δ 2.11 (tq, J = 5, 2.4 Hz, 2H), 1.78 (t, J = 2.5 Hz, 3H), 1.50-1.43 (m, 2H), 
1.37-1.34 (m, 2H), 1.26 (bs, 20H), 0.89-0.86 (m, 3H); 13C NMR (100 MHz, CDCl3) δ 79.6, 
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75.5, 32.1, 29.9, 29.8, 29.7, 29.4, 29.3, 29.1, 22.9, 18.9, 14.3, 3.6; HRMS (ESI-TOF): 
[M+H]+ Calc’d for C17H32 m/z 237.2582. Found, m/z. 237.2581. 
Hexadec-1-yne (18) 
 
(18) 
Lithium acetylide EDA complex (0.63 g, 6.86 mmol) was added to the stirring 
solution of 1-bromotetradecane (15) (1.0 g, 3.43 mmol) in dry DMSO (15 mL) and the 
resulted solution was stirred at room temperature overnight. The reaction progress was 
monitored by TLC. The reaction mixture was quenched with H2O (30 mL) and extracted 
with diethyl ether (3×10 mL). The organic extracts were washed with water (50 mL), brine 
(50 mL) and dried over anhydrous MgSO4. The solvent was removed in vacuo to give 15-
methylhexadec-1-yne as an oil, which was purified by column chromatography (straight 
hexane) to obtain 15-methylhexadec-1-yne (0.78 g, 2.69 mmol, 78%); IR (neat); 3313, 2922, 
2852, 1676, 1654, 1592, 1500,1485, 1466, 1430, 1404, 1379, 1350,1308, 1282, 1253,1194, 
1178, 1121, 1061, 1028 cm-1; 1H NMR (400 MHz, CDCl3) δ 2.18 (td, J = 7, 2.6 Hz, 2H), 
1.93 (t, J = 2.6 Hz, 1H), 1.56-1.49 (m, 2H), 1.40-1,37 (m, 2H), 1.26 (bs, 20H), 0.90-0.86 (m, 
3H); 13C NMR (100 MHz, CDCl3) δ 84.5, 68.2, 32.1, 29.9, 29.8, 29.7, 29.6, 29.3, 28.7, 22.9, 
18.6, 14.3; HRMS (ESI-TOF): [M+H]+ Calc’d for C16H30 m/z 223.2426.  Found, m/z 
223.2435. 
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Hexadec-2-yne (20) 
 
(20) 
IR (neat); 2920, 2852, 1464 cm-1;1H NMR (400 MHz, CDCl3) 1H NMR (400 MHz, CDCl3), 
δ 2.1 (tq, J = 7.8, 5.5 Hz, 2H), 1.78 (t, J = 2.5 Hz), 1.50-1.43 (m, 2H), 1.37-1.34 (m, 2H), 
1.26 (bs, 18H), 0.88 (t, J = 6.6 Hz, 3H); 13C NMR (100 MHz, CDCl3) δ 79.6, 75.5, 32.1, 
29.8, 29.7, 29.5, 29.4, 29.3, 29.1, 22.9, 18.9, 14.3, 3.7; HRMS (ESI-TOF): [M+H]+ Calc’d 
for C16H30. m/z 223.2426. Found, m/z 223.2429. 
EXPERIMENTAL WORK FOR OBTAINING THE KINETIC DATA  
Kinetic experiments were analyzed by NMR spectroscopy; in order to get the 
accurate integrations for the signals we have taken into consideration the T1 relaxation times. 
We ran T1 experiments on alkynes to find the right relaxation times.  The T1 experiments ran 
with the following VDLIST  
Table 6-7. VDLIST for T1 experiments 
S.No Variable delay values (sec) 
1 
2 
3 
4 
5 
6 
7 
8 
9 
10 
0.01 
0.100 
0.25 
0.500 
1 
2 
4 
8 
15 
25 
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The relaxation times for external and internal alkynes range from 1.296 sec to 8.613 
sec. The longest relaxation times were observed for alkyne protons in terminal alkynes and 
for propargylic protons in internal alkynes. We choose D1 as 30 sec and analyzed the kinetic 
data for all terminal alkynes ( >3*T1) (Table 6-8)  
Table 6-8. T1 relaxation of alkyne proton in terminal and terminal methyl in internal alkynes 
 
15-methylhexadec-1-yne (6) 
To a solution of 15-methylhexadec-1-yne (0.095 g, 40.2 mmol) in DMSO (10 mL) was 
added potassium tertiary butoxide (0.045 g, 40.2 mmol) and the resulting solution was heated 
in an oil bath at 55 °C and 75 °C. Every five minutes 0.5 mL aliquots were collected, 
quenched with water and extracted with hexane. The organic layer was dried over anhydrous 
MgSO4 and concentrated in vacuo to yield clear oil which was further analyzed by proton 
NMR using CDCl3 as a solvent.  
Alkyne T1 relaxation times (sec) 
hexadec-1-yne (16) 
hexadec-2-yne (20) 
7.249 
2.830 
heptadec-1-yne (18) 
heptadec-2-yne (19) 
7.712 
2.795 
15-methylhexadec-1-yne (6) 
15-methylhexadec-2-yne (8) 
8.613 
2.680 
octadec-1-yne (2) 
octadec-2-yne (7) 
6.740 
2.776 
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Octadec-1-yne (2)  
To a solution of 15 octadec-1-yne (0.1 g, 40.0 mmol) in DMSO (10 mL) was added 
potassium tertiary butoxide (0.045 g, 40.0 mmol) and the resulting solution was heated in an 
oil bath at 55 °C and 75 °C. Every five minutes 0.5 mL aliquots were collected, quenched 
with water and extracted with hexane.  The organic layer was dried over anhydrous MgSO4 
and concentrated to yield clear oil which was further analyzed by proton NMR using CDCl3 
as a solvent.  
The following procedure was followed for the kinetic experiments in fresh DMSO at 
70 °C, 40 °C and room temperature: 
To a solution of terminal alkyne (25.0 mmol) in DMSO (10 mL) was added potassium 
tertiary butoxide (0.028 g, 25.0 mmol) and the resulting solution was heated at 70 °C. At 
regular time intervals 0.1 mL aliquots were collected, quenched with water and extracted 
with hexane.  The organic layer was dried over anhydrous MgSO4 and concentrated to yield 
clear oil which was further analyzed by proton NMR using CDCl3 as a solvent.  
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